Curriculum Vitae: Richard David Smith
PERSONAL DETAILS
Contact Executive Suite Room F.01, University of Exeter Medical School, St Luke’s Campus, University of Exeter, Exeter, UK EX1 2LU. Tel: +44(0)1392 726076. Email: [email protected].
Date of birth 15th July 1968
Nationality British
QUALIFICATIONS
1990 BA (2:1) Economics, University of York 1991 MSc Health Economics, University of York 2007 PhD Health Economics, University of East Anglia. Title: The contingent valuation of healthcare benefits: methodological issues and development
EMPLOYMENT
1991-1993 Health Economist, Centre for Health Economics Research and Evaluation, Department of Community Medicine, University of Sydney, Sydney. 1993-1994 Consultant in Health Economics, Policy and Economics Group, Cambridge PharmaConsultancy, Cambridge. 1995-1996 Research Associate in Health Economics, Department of Social Medicine, University of Bristol, Bristol. 1996-1997 Lecturer in Health Economics, Health Economics Unit, Faculty of Business and Economics, Monash University, Melbourne. 1997-1999 Senior Lecturer in Health Economics, Health Economics Unit, Faculty of Business and Economics, Monash University, Melbourne. 1999-2003 Senior Lecturer in Health Economics, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich. 2003-2007 Reader in Health Economics, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich. 2007-2018 Professor of Health System Economics and Dean of Faculty, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine 2018-date Professor of Health Economics and Deputy Pro Vice Chancellor, College of Medicine and Health, University of Exeter
OTHER POSITIONS
1997-2007 Honorary Associate Professor in Health Economics, Department of Community Medicine, University of Hong Kong, Hong Kong. 2007-2011 Visiting Professor of Health Economics, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich. 2010-2013 Associate Fellow, Centre on Global Health Security, The Royal Institute of International Affairs, Chatham House, London. 2014-date Honorary Member of Faculty of Public Health, UK. 2015-2017 Associate Fellow, Public Health Genetics Foundation, Cambridge, UK 2015-2018 Member, Executive Board, International Health Economics Association 2018-date Honorary Professor of Health System Economics, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London 1 EDUCATION ACTIVITIES
University Courses developed and co-ordinated Health Economics component of the “Victorian Four University Consortium Masters of Public Health”, The University of Melbourne, Monash University, LaTrobe University and Deakin University, 1996 - 1997. Commonwealth Masters of Public Health, The University of Melbourne, 1998 - 1999 (co- development with Associate Professor Rob Carter). Certificate/Graduate Certificate in Health Economics by Distance Education, Monash University, 1996-1999. This eventually enrolled over 100 students from Australia and SE Asia each year, with three two-day workshops in 10 cities across three countries per year. MA Health Economics, School of Economics, University of East Anglia, 1999/2000 to 2005/6 (with Dr Sara Connolly from the School of Economics). ‘Health Economics’ module for 3rd year Economics undergraduates (joint with Dr Sara Connelly from the School of Economics), 2004/5 to 2005/6. MSc Health Economics, School of Medicine, Health Policy and Practice, University of East Anglia, 2006/7. MSc Global Health Policy (Distance Learning) (Developed jointly with Prof Kelley Lee), Department of Global Health and Development, London School of Hygiene and Tropical Medicine (launched October 2011) “The Global Economy and Health” module for the MSc Global Health Policy (Distance Learning) as above. Executive Programme for Global Health Leadership. A new, flagship, Executive Programme over 3 countries and 10 months, in collaboration with Graduate Institute in Geneva and University of Cape Town (launched September 2017). Master Public Health for Healthcare Business. Under development joint with University of Exeter Business School (to be launched September 2020).
Other University Courses co-ordinated Health Economics and Ethics Unit (M217) of the MSc Health Sciences, University of East Anglia, 1999/2000. Health Economics Unit (M207) of the MSc Health Sciences, University of East Anglia, 1999/2000. Director, Postgraduate taught programmes, University of East Anglia, 2000/2001 to 2003/2004.
Lectures and seminars conducted Three lectures on ‘Health Economics’ for the ‘Topics in Applied Economics’ course taken by Economic undergraduates at Sydney University, 1992. Four lectures for ‘Introduction to Health Economics’, an option for Master of Public Health postgraduates at Sydney University, 1992 and 1993. Three lectures in ‘Health Economics’, a component of Public Health Medicine for Fourth Year Medical Students at Bristol University, 1994/5 and 1995/6. Four lectures on ‘Benefit Valuation’ on the Graduate Diploma in Health Economics (for Economic postgraduates), Monash University, 1996 - 1998. Single lecture on ‘Health Economics and Finance’, Master of Health Finance and Management at LaTrobe University, Melbourne, 1998. Three lectures on ‘Health Economics’ for the Graduate Diploma in Clinical Health Management, Department of Epidemiology and Preventive Medicine, Monash University, 1999. Single lecture on ‘Health Economics’ for MSc Clinical Microbiology, Queen Mary’s School of Medicine and Dentistry, London, 2001/2 to 2004/5. 2 Two lectures on ‘Rationing’ for Health Economics Unit of the Master in Health Sciences, University of East Anglia, 2000/1 to 2004/5. Two lectures on ‘Contingent Valuation’ for Economic Evaluation Unit of the Master in Health Sciences, University of East Anglia, 2000/1 to 2004/5. Two lectures on ‘Valuation of health benefits’ for Master of Studies programme, Cambridge University Department of Public Health, 2002/3 to 2003/4. Ad hoc lectures and examining for MBBS students, University of East Anglia, 2005-7. Lecture on ‘Supplier-induced demand’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2007/8. Lecture on ‘An overview of the global economy’ for Globalization and Health module of MSc Public Health Health, London School of Hygiene and Tropical Medicine, 2007/8- date. Lecture on ‘Human resources and (health care worker) migration’ for Economic Analysis for Health Policy module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2007/8. Lecture on ‘The challenges for national health systems in a globalizing world’ for Health Systems module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2007/8-2010/11. Lecture on ‘Introduction to health economics’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Key concepts in health economics’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Consumers and the demand for health (care)’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Producers and the supply of health (care)’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Resource allocation and ‘the market’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Information, supplier induced demand and provider responses to incentives’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘‘Regulating’ health care markets’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Non-market health care allocation’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Introduction to the economic evaluation of health services’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Health Economics in practice – a ‘how to’ and questions’ for Introduction to Health Economics Module of MSc Public Health, London School of Hygiene and Tropical Medicine, 2008/9-2010/11. Lecture on ‘Trade and health’ for BSc International Health Policy, University College London, 2008/9-2011/12. Lecture/seminar on Health Economics for BSc Medical Sciences module on ‘Measurement and Evaluation in Health Research’, University of Exeter, 2018/19-date 3 Lecture on ‘sugar taxes’ for BMBS Special Study Unit on ‘Health Inequalities’, University of Exeter, 2018/19-date
Workshops developed and presented Sydney University Health Economics workshop, 4-8th November 1991, for health professionals. ‘Introductory Health Services Research Workshop’, Cheltenham General Hospital, 24th May 1995 and Bristol Royal Infirmary, 27th July & 26th Sept. 1995, and 15th Feb. 1996, for health professionals. ‘Introductory Economic Evaluation Workshop’, United Bristol Healthcare Trust, 18th July 1995, for health professionals. ‘Public Health Trainees: Economic Evaluation Workshop’, Victorian Department of Human Services, Melbourne, 3rd October 1997, for public health doctors. Primary Care Group Workshops, University of East Anglia, 30th June, 1st, 21st, 22nd, 28th and 29th July, 5th August 1999, for members of PCG/Ts. Lecture on ‘Globalization, trade and health’ for UNICEF short-course at LSHTM, September 2010-2018.
Postgraduate Students Supervised Masters Dono Widiatmoko (MSc). Thesis entitled Disability prevention in the elderly: an economic model, awarded 1996. Letizia Orzella (MSc). Thesis entitled Health outcomes evaluation: monetary or utility terms?, awarded 1997. Trefor Jones (MEcon). Thesis entitled Contingent Valuation in Health Programme Evaluation, awarded 1998. Paula Wilton (MEcon). Thesis entitled Reform of Australian General Practice: A budget- holding model?, awarded 1999. Nick Raithatha (MSc). Thesis entitled Risk perception and vaccination, awarded 2002. Clare Daly (MSc). Thesis concerned with perception of lifestyle intervention for heart failure patients, awarded 2006. Many LSHTM MSc students!
Doctoral (all passed with only minor corrections) Richard Holland (PhD). Thesis entitled An Evaluation of Domiciliary Medication Review by pharmacists in older patients, awarded 2005 (examiners Dr Philip Shackley, University of Newcastle and Prof Tim Peters, University of Bristol). Phyo Kyaw Myint (MD). Thesis entitled Healthy Ageing: Determinants and Outcomes of Self-reported Functional Health in the EPIC-Norfolk Cohort, awarded 2007. Philip Kinghorn (PhD). Thesis entitled Developing a Capability Approach to Measure and. Value Quality of Life: An application to chronic pain, awarded 2010 (examiners Prof Joanna Coast, University of Birmingham and Dr Richard Holland, University of East Anglia). Inthira Yamabhai (PhD). Thesis entitled Heath And Economic Implications Of Patent Protection For Pharmaceuticals: A Case-Study Of Thailand, awarded 2013 (examiners, Prof Panox Kanvos LSE, Prof Rachel Elliot, Nottingham). Gillian Stynes (PhD). Thesis entitled The Role of Professional Education in Pharmacist Migration from Sub-Saharan Africa, awarded 2013 (examiners Prof Mandy Ryan, Aberdeen, Prof John Cairns, LSHTM). Winner of 2013/14 Jerry Morris Prize (LSHTM). Rachel Irwin (PhD). Thesis entitled Global Health Diplomacy and the World Health Organization: a ‘social drama’, awarded 2014 (examiners Dr Emma Crewe, SOAS, Prof Ian Harper, Edinburgh). 4 Suriwan Thaiprayoon (PhD). Thesis entitled Health and trade negotiations: a case study of the Thai Ministry of Public Health, awarded 2014 (examiners Prof Jeff Collin, Edinburgh, Dr Preslava Stoeva, LSHTM). Thinakorn Noree (PhD). Thesis entitled The impact of medical tourism on the domestic economy and health system: a case study of Thailand, awarded 2014 (examiners Prof David Hughes, Cardiff, and Dr. Jolene Skordis-Worrall, UCL). Judith Kabujuluzi (PhD). Thesis entitled Macroeconomic implications of health sector reforms: a computable general equilibrium analysis of Uganda, awarded 2016 (examiners Prof Marc Surce, York, Dr Milton Yago, Leeds). Robert Marten (PhD, part-time). Thesis entitled State Power in Global Health Policymaking: Case-studies of Japanese and Indonesian Engagement in the Development of the Sustainable Development Goal for Health (SDG3), awarded 2019 (examiners Prof Clare Wenham, LSE, Dr Simon Rushton, Sheffield). Toby Watt. Thesis entitled Impact of food price promotions on consumer behaviour and public health, current (2016) Penelope Milson (PhD). Assessing health impacts of the investor-state dispute settlement provision in contemporary trade and investment agreements: case-studies of tobacco control, access to essential medicines and environmental health, current (2016).
Advisory Panel (all LSHTM students) May Yeung (DrPH). Advisory panel, 2007-2010 (also acted as temporary supervisor (2007) whilst main supervisor (Richard Coker) on sabbatical). Mylene Lagarde (PhD). Advisory Panel, 2007-2010. Mardziah Ahmad Sanudi (PhD). Advisory Panel, 2009-2013. Noah Scovronick (PhD). Advisory Panel, 2010-2014. Christine Michaels (PhD). Advisory Panel, 2010-2015. Elisa Ricciuti (PhD). Advisory Panel, 2011-2015. Houda Bennani (PhD). Advisory Panel. 2018-2021.
PhD Students Examined Nicola Cooper, internal examiner, University of East Anglia, UEA, 2001. Thesis entitled “The economic impact of rheumatoid arthritis in the first five years”. Mohammed Amin, external examiner, London School of Hygiene and Tropical Medicine, 2002. Thesis entitled “An analysis of private hospital markets in Bangladesh”. Pa Lamin Beyai, external examiner, London School of Hygiene and Tropical Medicine, 2006. Thesis entitled “Exploring the measurement of indirect costs via an Economic evaluation of intermittent preventative treatment for pregnant Gambian women”. Lara Fairall, external examiner, University of Cape Town, 2007. Thesis entitled “The costs and effects of the Practical Approach to Lung Health in South Africa”. Katherine Bolt, external examiner, University of East Anglia, 2007. Thesis entitled “Estimating a value of statistical life for children in the UK”. Grace Jennings, internal examiner, London School of Hygiene and Tropical Medicine, 2008. Thesis entitled “Balancing risks: international policy on emerging infectious disease and biological warfare control programmes”. Jon Mortensen, external examiner, University of Copenhagen, 2008. Thesis entitled “Exporting healthcare: how trade and trade liberalization in health services impact developing countries – a case study of South Africa”. Maria Santamaria, internal examiner, London School of Hygiene and Tropical Medicine, 2009. Thesis entitled “The challenge of assessing the performance of multilateral development agencies: lessons from WHO programmes in Myanmar and in Nepal”.
5 Carl Tilling, external examiner, University of Sheffield, 2010. Thesis entitled “An examination of two key issues surrounding the future of economic evaluation: the inclusion of productivity costs and the elicitation of a monetary value for the QALY”. Rohan Sweeney, external examiner, Monash University, 2015. Thesis entitled “The economics of coordinating health aid: investigating the sector wide approach”. Magda Aguiar, external examiner, University of Birmingham, 2017. Thesis entitled “Decision analytic modelling of the prevention of vitamin D deficiency in England and Wales”. Nicola Naylor, external examiner, Imperial College London, 2018. Thesis entitled “The Burden of Antimicrobial Resistance: The Case of Escherichia coli”.
University of East Anglia MBBS ‘internship’ supervision I also supervised UEA BMBS students who wished to enrol for WHO internships, either on a voluntary basis or as part of their placement period.
Pastoral I have been personal tutor for many students during my career at all institutions where I have worked.
6 RESEARCH GRANTS (PI LISTED FIRST ON ALL GRANTS)
1. Shiell A, Smith RD. Feasibility of using willingness to pay to value road safety programmes. Federal Office of Road Safety, 1992: AU$19,227. 2. Gurney HG, Smith RD, Harnett PR, King M, Hall J. Prospective evaluation of a domicilliary chemotherapy programme in NSW. New South Wales Cancer Council ‘Patient Care Award’, 1993: AU$57,452. 3. Smith A, Harvey I, Peters T, Davey-Smith G, Smith RD, Harling K. The scale and costs of occupational stress. Health and Safety Executive, 1995: £225,176. 4. Hanks GW, O’Neill WM, Sharp D, Robbins M, Smith RD. Impact of an hospital-based palliative care service on care in the community. National Health Service Executive, 1995: £195,628. 5. Nelson R, Findlay G, Greenfield K, Smith RD. A randomised controlled trial of microdiscectomy and conservative treatment for sciatica and discogenic low back pain. National Health Service Executive, 1995: £152,000. 6. Coast J, Donovan J, Morgan K, Eyles J, Abelson J, Sheperd M, Smith RD. The organisation of purchasing care: involving the public in local decision making for health care. South and West Regional Health Authority R&D Directorate, 1996: £111,770. 7. Long H, Naccarella L, Summers M, Dunt, D, Batterham R, Pirkis J, Smith RD. Identification and evaluation of innovative models of mental health service delivery for NESB communities. The Australian Transcultural Mental Health Network, 1996: AU$53,013. 8. Smith RD, Harris A, Abel-Olsen J. The valuation of health outcomes in monetary terms. Commonwealth Department of Health and Family Services, 1997: AU$33,600. 9. Richardson J, Smith RD, Hawthorne G, Abel-Olsen J. The measurement and valuation of utility-based quality of life. Commonwealth Department of Health and Family Services, 1997: AU$28,023. 10. Smith RD. A pilot analysis of the feasibility of developing a ‘generic’ willingness-to-pay instrument for the valuation of health states in the economic evaluation of health care interventions. Faculty of Business and Economics, Monash University, 1997: AU$13,943. 11. Hawthorne G, Richardson J, Smith RD, Day N, Mathers C. Simultaneous validation of the AQoL instrument and the DALY using post-deliberation utilities. National Health and Medical Research Council, 1998: AU$389,276. 12. Smith RD. PCG economic and policy advice function. Norfolk and Suffolk Education and Training Consortium, 2000: £30,319 13. Smith RD, Charlesworth G, Shemmings D. Evaluation of Prevention, Carers and Partnership Plans. Norfolk County Council Social Services, 2000: £51,000. 14. Holland R, Harvey I, Shepstone L, Christou M, Smith RD. Randomised controlled trial and economic evaluation of domiciliary medication review by pharmacists. Medical Research Council, NHS Executive, Eastern Region, and Norfolk Health Authority, Suffolk Health Authority, Norfolk Social Services, 2000-2003: £250,919 15. Smith RD, Coast J, Millar MM. Cost effectiveness analysis: interventions against anti- microbial resistance. World Health Organization, 2000: £11,760. 16. Smith RD, Coast J, Millar MM, Mills A. Development of an economic model of antimicrobial resistance. The World Health Organisation, 2001: £54,500. 17. Smith RD, Coast J, Millar MM. Development of an economic model of antimicrobial resistance. The Nuffield Trust, 2001: £51,628. 18. Smith RD. Global Public Goods for Health. World Health Organisation, 2001: US$80,500. 19. Mugford M, Smith RD, Cookson R, Fordham R. Health economics support for the NHS public health function. Cambridge and Norfolk Health Authorities, 2000-2007: £211,926.
7 20. Smith RD. Commercial presence and foreign direct investment: impact on health. World Health Organisation, 2002: US$6,000. 21. Loomes G, Sugden R, Bateman I, Smith RD, Robinson A. What is the Value to Society of a QALY? An Investigation Among the Public of England and Wales. Department of Health, 2002: £7,200. 22. Smith RD. Bursaries for student projects on MSc in Health Sciences. Norfolk Public Health Network (via Norwich PCT), 2003: £8,500. 23. Holland R, Harvey I, Christou M, Smith RD, Howe A, Shepstone L, Brooksby I. Randomised controlled trial and economic evaluation of domiciliary medication review by pharmacists for patients with cardiac failure in Norfolk. British Heart Foundation, 2003: £157,671. 24. Smith RD, Koutantji M, Scott DGI. A study to evaluate the costs and impact of anti- TNF drugs in patients with Rheumatoid Arthritis. John Wyeth and Brother Ltd, 2003: £458,478. 25. Yeung RYT, Smith RD, Leung GM, McGhee SM. The economics of vaccination: willingness to pay and values clarification. Research Grants Council, Hong Kong SAR, 2003: HK$576,085. 26. Smith RD. The economics of SARS. World Health Organisation, 2003: US$25,000. 27. Smith RD. Trade in health services and GATS: development of framework for country analysis. World Health Organisation, 2003: US$14,000. 28. Donaldson C, Bateman I, Chilton S, Jones-Lee M, Loomes G, Metcalf H, Mugford M, Robinson A, Ryan M, Shackley P, Smith RD, Sugden R, Wildman J (alphabetical after PI). What is the value to society of a QALY? Department of Health, 2003: £434,832. 29. Smith RD. Health economics futures. The Nuffield Trust, 2004: £4,000. 30. Smith RD. Priority-setting and Genetics. The Nuffield Trust, 2004: £2,000. 31. Abraham T, Aerts M, Beutels P, Desenclos JC, Edmunds J, Eichner M, Ganter B, van Genugten M, Keeling M, Merianos A, Ruutu P, Salmaso S, Smith RD, Wallinga J, Wang T (alphabetical). Strengthening public health policy in Europe for new and emerging infections through risk assessment, mathematical modelling, economic analysis and risk communication. European Union Framework 6, 2004: €2,500,000. 32. Smith RD. Measuring Globalization and health: developing an index of openness of health services to trade. World Health Organisation, 2004: US$9,900. 33. Goossens H, Bernard C, Beutels P, Blasi F, Butler C, Coast J, Edmunds J, Fahey T, Finch R, Hill A, Little P, Smith RD, Spaan W, Torres A, Verheij T, Weber M (alphabetical after PI). Genomics to combat Resistance against Antibiotics in Community acquired LRTI in Europe (GRACE). European Union Framework 6, 2005: €11,501,003. 34. Smith RD. Global health governance and public health. World Health Organisation, 2006: US$12,500. 35. Verheij T, Blasi F, Butler C, Coast J, Godycki-Cwirko M, Goossens H, Harbarth S, Little P, Ridder R, Rodriguez J, Smith RD (alphabetical after PI). CHAMP (Changing behaviour of Health care professionals And the general public towards a More Prudent use of anti-microbial agents). EU FP6, €1,445,260. 36. Donaldson C, Brouwer W, Gulacsi L, Gyrd-Hansen D, Kozierkiewicz A, Olsen JA, Manca A, Mataria A, Moatti JP, Persson U, Pinto Prades JL, Ryan M, Smith RD (alphabetical after PI). European Value of a Quality Adjusted Life Year. European Union Framework 6, 2006-20011: €1,499,995. 37. Smith RD. Mapping non-health impacts on health over coming decades for WHO, 2008, $9,000. 38. Smith RD. Applying CGE model of pandemic influenza to UK finance sector, ESRC and Department of Health, 2008, £4,500 39. Smith RD, Lagarde M, Hanson K. An experimental investigation of social preferences, their determinants and their role in the labour supply function. ESRC, 2009-10, £94,000.
8 40. Smith RD, Oketch M, Smith F. The role of professional education and training in workforce migration. The Bloomsbury Colleges PhD studentships 2009-2011 (fees, plus £4,000 from LIDC towards field work). 41. Smith RD, Chanda R. Prospects for Telemedicine and Medical Tourism between India and UK. British Council (UK-India Education and Research Initiative), 2009-10, £36,356. 42. Read JM, Crowcroft J, Edmunds J, Michie S, Smith RD, Yardley L (alphabetical after PI). Understanding behavioural responses to infectious disease outbreaks. ESRC/BBSRC/MRC UIBEN, 2009/10, £214,256. 43. Waage J, Dangour A, Smith RD, Dorward A, Johnston D, West H, Heinrich M, Rushton J. Building an Agri-Health Discipline to link Agricultural and Health Research. Leverhulme, 2010-2015, £3,498,941. 44. Smith RD, McDonald S, Drakely C, Keogh-Brown M, Arndt C, Jensen H. Methodological development of whole-economy modelling of infectious disease: P. falciparum malaria control in Africa. Medical Research Council, 2010-2013, £680,000. 45. Coker R, Waage J, Smith RD. The impact on zoonotic disease of developments in livestock production, distribution and consumption. MRC/ESRC/BBSRC/NERC catalyst grant for Ecology of Infectious Disease, £50,000. 46. Lunt N, Smith RD, Mannion R, Green ST, Exworthy M. Implications for the NHS of inward and outward Medical Tourism. NIHR Health Services Research programme, 2010-2012, £279,000. 47. Smith RD, Lee K. Research programme on global health diplomacy. Rockefeller Foundation, 2010-2011, US$253,170. 48. Haines A, Smith RD, Griffiths U, Wilkinson P, Roberts I, Edwards P, Dangour A. Health economic assessment of health co-benefits of policies to reduce greenhouse gas emissions. Department of Health, Policy Research Programme, 2011, £89,973. 49. Smith RD, Haddad L, Haines A, Waage J. Integrating Research on Health and Development: Evidence Building and Researcher Engagement. Department for International Development, 2011-2012, £253,204. 50. Smith RD, Venkatapuram S. Capabilities theory and global population-level bioethics. Wellcome Trust, 2011-2014, £180,783. 51. Smith RD, Shankar B. Towards a healthier and environmentally sustainable edible oil consumption profile for Asia. Wellcome Trust, 2014-2016, £298,359. 52. Hanefeld J, Smith RD, Gilson L, Lunt N. Strengthening health system promotion of maternal and child health through medical travel. Medical Research Council-Wellcome Trust Joint Health Systems Research Initiative (Stage 1: Development), 2014-2015, £101,781. 53. Cornelsen L, Smith RD. Direct and indirect impact of food taxes and subsidies on food consumption and population health. Medical Research Council Fellowship (for Cornelsen, supervised by Smith), 2014-2016, £400,782. 54. Marteau T, Roland M, Smith RD, Griffin S, Ogilvie D, Jebb S, Suhrcke M, Zizzo D, Ling T. Policy Research Unit in Behaviour and Health. Department of Health, 01.01.16 to 31.12.18 – [LSHTM lead: £240,000]. 55. Greco G, Mills A, Smith RD. Developing a wellbeing measure for public health evaluations: integrating capabilities and happiness. Medical Research Council Fellowship (for Greco, supervised by Mills and Smith), 2015-2017, £367,476. 56. Dangour AD, Chalabi Z, Ezzati M, Green R, Haines A, Myers S, Smith RD, Wheeler T [alphabetical after PI). Future diets and health: How will environmental changes affect food availability, food consumption and health? Wellcome Trust, 2015-2017, £403,871. 57. Cornelson, L, Smith RD, Beckert W. Impact of food price promotions on consumer behaviour and public health. The Bloomsbury Colleges PhD studentships 2016-2019 (fees).
9 58. Cummins S, Thompson C, Petticrew M, Smith RD, Cornelsen L, Knai C, White M, Adams J, Mytton O. Evaluation of the impacts of a levy on added-sugar drinks within commercial restaurant environments: implementation, impact on sales, acceptability, modelling of health impacts and economic evaluation. NIHR Rapid Funding, 2016, £47,480. 59. White M, Cummins S, Rayner M, Smith RD, Adams J, Scarborough P, Mytton O, Rutter H, Briggs A, Monsivais P. Evaluation of the impacts on health of the proposed UK industry levy on sugar sweetened beverages: developing a systems map and data platform, and collection of baseline and early impact data. NIHR Rapid Funding, 2016, £49,959. 60. Smith RD, Shankar B. Palm Oil: Sustainability, Health and Economics (POSHE). Wellcome Trust, 2016-2018, £200,000. 61. Petticrew M, Lock K, Egan M, Cummins S, Smith RD. NIHR School for Public Health Research (Phase 2). NIHR, 2017-2022, £1,537,481 [LSHTM share]. 62. Walls H, Smith RD, Johnston D. Do agricultural input subsidies on staples reduce dietary diversity? Drivers of Food Choice Competitive Grants Program funded by the Bill & Melinda Gates Foundation and the UK Department for International Development, 2016-2018, £299,424. 63. Smith RD, Milson P. Assessing health impacts of the investor-state dispute settlement provision in contemporary trade and investment agreements: Case-studies of tobacco control, access to essential medicines and environmental health. Wellcome Trust Society & Ethics Doctoral Studentship for Penelope Milsom, 2016-2019 £105,223. 64. Dangour AD, Haines A, Smith RD, Green R, Cornelsen L, Kadiyala S, Knai C, Leon D, Waage J. Sustainable and Healthy Food Systems (SHEFS) Wellcome Trust, 2017-2022, £5,000,000. 65. White M, Smith RD, Cummins S, Rutter H, Rayner M, Scarborough P, Briggs A, Harrington R, Adams J, Mytton O. Evaluation of the impacts of the UK Treasury Soft Drinks Industry Levy (SDIL). NIHR, £1,500,000, 2017-2020. 66. Cornelsen L, Smith RD. Role of food prices and food system changes in improving population health. MRC Career Development Award for Cornelsen, £500,000, 2017- 2022. 67. Petticrew M, Egan M, Lock K, Cummins S, Smith RD. Developing a systems perspective for the evaluation of local public health interventions: theory, methods and practice. SPHR project (from core monies to be bid for), 2018-2019, £148,593. 68. Hanefeld J, Walls H, Smith RD, Vearey J, Gilson L. Gender, migration and health system responses in South Africa: A focus on the movement of healthcare users and workers. MRC HSRI, £683,167, 2019-2021. 69. Kingston P, Garde A, Hunter P, Lincoln P, Mabhala M, Manning P, Parish R, Pencheon D, Sassi F, Smith RD, Winters A [alphabetical after PI]. PETRA: Prevention of Disease Using Trade Agreements. UKPRP Network Award, MRC, £400,000, 2019-2022. 70. Adger N, Smith RD, Quinn T, Murphy C, Codjo S, Morrissey K. Evaluating Health Impacts of Climate Adaptation Strategies. Wellcome Trust, £489,850, 2019-2022. 71. Adams J, White M, Robinson E, Burgoine T, Smith RD, Jones A, Bishop T, Sharp S. Implementation and assessment of mandatory calorie labelling in the out-of-home sector. NIHR PRP, £649,726, 2019-2022.
10 PUBLICATIONS (ORCID: 0000-0003-3837-6559)
Books 1. Smith RD, Beaglehole R, Woodward D, Drager N (eds). Global Public Goods for Health: a health economic and public health perspective, Oxford University Press, 2003. 2. Blouin C, Drager N, Smith RD (eds). International Trade in Health Services and the GATS: Current Issues and Debates. World Bank, 2006. 3. Smith RD, Hanson K (eds). Health systems in low- and middle-income countries: an economic and policy perspective. Oxford University Press, 2012. 4. Smith RD. Section editor on Health and the Macroeconomy and author of several entries for: Culyer, A (ed), Encyclopedia of Health Economics. San Diego: Elsevier; 2014. 5. Smith RD, Blouin C, Mirza Z, Beyer P, Drager N (eds). Trade and Health: Towards building a National Strategy. Geneva: World Health Organization; 2015. 6. Smith RD. Editorial Board for World Scientific Handbook of Global Health Economics and Public Policy for: Scheffler, RM (ed). New Jersey: World Scientific; 2015.
Chapter in a book 1. Smith RD, Salter B. Citizen, consumer or both? Re-conceptualising ‘demand’ in health care. Health Policy and Economics: Strategic Issues in Health Care Management, M Tavakoli, HTO Davies & M Malek (eds), Ashgate Publishing Ltd, 2001; Chapter 9. 2. Smith RD, Beagehole R, Woodward D, Drager N. Global public goods for health: from theory to policy. In: Smith RD, Beaglehole R, Woodward D, Drager N (eds). Global Public Goods for Health: a health economic and public health perspective, Oxford University Press, 2003, chapter 14. 3. Woodward D, Smith RD. Global Public Goods for Health: concepts and issues. In: Smith RD, Beaglehole R, Woodward D, Drager N (eds). Global Public Goods for Health: a health economic and public health perspective, Oxford University Press, 2003, chapter 1. 4. Smith RD, Coast J. Antimicrobial drug resistance. In: Smith RD, Beaglehole R, Woodward D, Drager N (eds). Global Public Goods for Health: a health economic and public health perspective, Oxford University Press, 2003, chapter 4. 5. Thorsteinsdóttir H, Daar A, Smith RD, Singer P. Genomics knowledge. In: Smith RD, Beaglehole R, Woodward D, Drager N (eds). Global Public Goods for Health: a health economic and public health perspective, Oxford University Press, 2003, chapter 7. 6. Smith RD, Woodward D. Global public goods for health: use and limitations. In: Smith RD, Beaglehole R, Woodward D, Drager N (eds). Global Public Goods for Health: a health economic and public health perspective, Oxford University Press, 2003, chapter 13. 7. Smith R. What does economics have to offer in the war against antimicrobial resistance. In: Knobler SL, Lemon SM, Najafi M, Burroughs T (eds), The resistance phenomenon in microbes and infectious disease vectors: implications for human health and strategies for containment. National Academy Press, Washington, DC, 2003: chapter 4. 8. Thorsteinsdóttir H, Daar AS, Smith RD, Singer PA. Do Patents Encourage or Inhibit Genomics as a Global Public Good? In Knoppers BM (ed.), Populations and Genetics: Legal and Socio-Ethical Perspectives. Martinus Nijhoff Publishers, Leiden/Boston, 2004; pp 487-504. 9. Smith RD, Blouin C, Drager N. Trade in health services and the GATS: an introduction. In: Blouin C, Drager N, Smith RD (eds). Trade in Health Services, developing countries and the GATS. World Bank, 2006: chapter 1. 10. Chanda R, Smith RD. Trade in health services and GATS: a framework for policy makers. In: Blouin C, Drager N, Smith RD (eds). Trade in Health Services, developing countries and the GATS. World Bank, 2006: chapter 3.
11 11. Blouin C, Lethridge J, Singh D, Smith RD, Warner D. Trade in health services under the four modes of supply: a review of current trends and policy issues. In: Blouin C, Drager N, Smith RD (eds). Trade in Health Services, developing countries and the GATS. World Bank, 2006: chapter 10. 12. Gobrecht J, Smith RD, Drager N. Measuring trade in health services. In: Blouin C, Drager N, Smith RD (eds). Trade in Health Services, developing countries and the GATS. World Bank, 2006: chapter 11. 13. Smith RD, Blouin C, Drager N. Trade in health services and the GATS: what next? In: Blouin C, Drager N, Smith RD (eds). Trade in Health Services, developing countries and the GATS. World Bank, 2006: chapter 12. 14. Coast J, Smith RD, Millar MR. Disentangling value: assessing the benefits of containing antimicrobial resistance. In: Roberts J (ed). The Economics of Infectious Disease. Oxford University Press, New York, 2006: chapter 11, pp201-214. 15. Smith RD. Trade in Health Services: Current Challenges and Future Prospects of Globalisation. In: Jones AM (ed). Elgar Companion to Health Economics. Edward Elgar, 2006: chapter 16. 16. Smith RD, Blouin C, Drager N, Fidler DP. Trade in health services and the GATS. In: Mattoo A, Stern RM, Zanini G (eds). A handbook of international trade in services. Oxford University Press, 2007: chapter 11 (pp437-458). 17. Thorsteinsdóttir H, Smith RD, Daar AS, Singer PA. A global public good’s perspective on the promoting and financing of genomics. In: Mordini E (ed). Ethics and Health in the Global Village – Bioethics, Globalization and Human Rights. CIC Edizioni Internazionali, Roma, 2009: chapter 7 (pp175-191). 18. Smith RD. Global Health Governance and Global Public Goods. In: Buse K, Hein W, Drager N (eds). Making Sense of Global Health Governance - A policy perspective. Palgrave Macmillan, Basingstoke, 2009: chapter 6 (pp122-136). 19. Smith RD, Sach TH. Contingent valuation. In: Kattan MW (ed). Encyclopedia of Medical Decision Making. Thousand Oaks, CA: Sage Publications, 2009; 1: 202-205. 20. Smith RD. Trade in Health Services: Current Challenges and Future Prospects of Globalisation. In: Jones AM (ed). Elgar Companion to Health Economics. Edward Elgar, 2nd edition, 2011: chapter 16; p164-175. 21. Smith RD, Lorgelly P, Al-Janabi H, Venkatapuram S, Coast, J. The Capability Approach: an alternative evaluation paradigm for health economics? In: Jones AM (ed). Elgar Companion to Health Economics. Edward Elgar, 2nd edition, 2011: chapter 39; p415-424. 22. Smith RD, Hanson K. What is a ‘health system’? In: Smith RD, Hanson K (eds). Health systems in low- and middle-income countries: an economic and policy perspective. Oxford University Press, 2012: chapter 1. 23. Yadav P, Smith RD, Hanson K. Pharmaceuticals and the health sector. In: Smith RD, Hanson K (eds). Health systems in low- and middle-income countries: an economic and policy perspective. Oxford University Press, 2012: chapter 7. 24. Smith RD. The health system and international trade. In: Smith RD, Hanson K (eds). Health systems in low- and middle-income countries: an economic and policy perspective. Oxford University Press, 2012: chapter 8. 25. Smith RD. The health system and global changes. In: Smith RD, Hanson K (eds). Health systems in low- and middle-income countries: an economic and policy perspective. Oxford University Press, 2012: chapter 11. 26. Smith RD, Hanson K. Global health diplomacy: the ‘missing pillar’ of health system strengthening. In: Smith RD, Hanson K (eds). Health systems in low- and middle-income countries: an economic and policy perspective. Oxford University Press, 2012: chapter 12. 27. Smith RD. Macroeconomics, globalization and health. In: Guiness L and Wiseman V (eds). Introduction to Health Economics. McGraw-Hill, 2011 (2nd edition): chapter 2.
12 28. Smith RD, Legido-Quigley H, Lunt H, Horsfall D. Medical Tourism: the European way. In: Hodges J, Turner L, Kimball AM (eds). Risks and challenges in medical tourism: understanding the global market for health services. Praeger, 2012: chapter 3. 29. Martínez Álvarez M, Smith RD, Chanda R. The impact of medical tourism in low- and middle-income countries. In: Botterill D, Pennings G, Mainil Y (eds). Medical Tourism and Transnational Health Care, Palgrave Macmillan, 2013: chapter 13. 30. Horsfall D, Lunt N, King H, Hanefeld J, Smith RD. The Impact of the Internet on Medical Tourism. In: Botterill D, Pennings G, Mainil Y (eds). Medical Tourism and Transnational Health Care, Palgrave Macmillan, 2013: chapter 14. 31. Lunt N, Hanefeld J, Horsfall D, Smith RD. The UK National Health Service and International Patients. In: Smith M, Puczko L, editors, Health, Tourism and Hospitality: Spas, Wellness and Medical Travel. 2nd ed. Routledge. 2013: chapter 47. 32. Smith RD. Global Public Goods and Health. In: Anthony J. Culyer (ed.), Encyclopedia of Health Economics, Vol 1. San Diego: Elsevier; 2014. pp. 322-326. 33. Smith RD. Health and Health Care, Macroeconomics of. In: Anthony J. Culyer (ed.), Encyclopedia of Health Economics, Vol 1. San Diego: Elsevier; 2014. pp. 327-332 34. Walls H, Hanefeld J, Smith RD, Drager N, Lee K. Trade and global health. In: Hanefeld J (ed.), Globalization and Health (2nd edition). Berkshire: Open University Press; 2015. Chapter 8: pp. 100-113. 35. Hanefeld J, Smith RD. Globalization and trade in health services. In: Lunt N, Horsfall D, Hanefeld J (ed.), Handbook on Medical Tourism and Patient Mobility, Edward Elgar; 2015. Chapter 4, pp 37-44. 36. Hanefeld J, Smith RD. Financing mechanisms. In: Lunt N, Horsfall D, Hanefeld J (ed.), Handbook on Medical Tourism and Patient Mobility, Edward Elgar; 2015. Chapter 10, pp 104-111. 37. Smith RD, Blouin C, Drager N. Trade and health - the linkages. In: Smith RD, Blouin C, Mirza Z, Beyer P, Drager N (eds.). Trade and Health: Towards building a National Strategy. Geneva: World Health Organization; 2015. Chapter 1, pp1-7. 38. Smith RD, Blouin C. Macroeconomic aspects of trade and health. In: Smith RD, Blouin C, Mirza Z, Beyer P, Drager N (eds.). Trade and Health: Towards building a National Strategy. Geneva: World Health Organization; 2015. Chapter 4, pp 35-45. 39. Smith RD, Keogh-Brown M, Hanefeld J. Macroeconomics, Trade and Health. In: Scheffler, RM (ed.), World Scientific Handbook of Global Health Economics and Public Policy, World Scientific; 2015. Volume 1; Chapter 2. 40. Hanefeld J, Noree T, Smith RD. Medical Tourism. In: Scheffler, RM (ed.), World Scientific Handbook of Global Health Economics and Public Policy, World Scientific; 2015. Volume 3; Chapter 8. 41. Smith RD. E-learning and MOOCs: The experience from the London School of Hygiene & Tropical Medicine. In: Chan LS (ed), MOOCs in Postmodern Asia, Li Ka Shing Faculty of Medicine, University of Hong Kong, 2016: chapter 1 (pp2-11). 42. Smith RD, Prah Ruger J, Jamison DT, Bloom DE, Canning D. Health and the Economy. In: Merson M, Black R, Mills A (eds), “Global Health: diseases, programs, systems and policies”, Jones & Bartlett Learning, LLC; 2018. Chapter 19: 835-855. 43. Hanefeld J, Smith RD, Chanda R. International Trade and Health. In: Merson et al “Global Health” (submitted). 44. Smith RD, Coast J. The economics of resistance through an ethical lens. In: Jamrozik Z (ed) Ethics and Drug Resistance: Collective Responsibility for Global Public Health (in press), Springer; chapter 9. 45. Smith RD, Hanefeld J. Globalization, Trade, and Health Economics. In: Hamilton J (ed), Oxford Research Encyclopaedia of Economics and Finance, 2018; DOI: 10.1093/acrefore/9780190625979.013.35: http://economics.oxfordre.com/view/10.1093/acrefore/9780190625979.001.0001/acrefore -9780190625979-e-35
13 46. Smith RD, Hanefeld J. Globalization, Trade, and Health Economics. In: Jones AM (ed). Oxford Encyclopaedia of Health Economics (submitted) [print version of on-line chapter above]. 47. Irwin R, Smith RD. The virus sharing controversy: Global health diplomacy as social drama. In: Bresalier M (ed). One Hundred Years of Pandemic Influenza. Routledge, 2018; chapter 20. (In press: https://www.routledge.com/One-Hundred-Years-of- Pandemic-Influenza/Bresalier/p/book/9781138354241)
Article in a journal 1. Smith RD, Dobson M. Measuring utility values for QALYs: two methodological issues. Health Economics, 1993; 2(4): 349-355. 2. Smith RD, Hall J, Gurney HG, Harnett PR. A cost-utility approach to the use of 5- fluorouracil and levamisole as adjuvant chemotherapy for Dukes’ C colonic carcinoma. Medical Journal of Australia, 1993; 158(5): 319-322. 3. Shiell A, Smith RD. A tentative cost-utility analysis of road safety education. Australian Journal of Public Health, 1993; 17(2): 128-130. 4. Scott A, Smith RD. Keeping the customer satisfied: interpreting and using the results of patient satisfaction surveys. International Journal of Quality in Health Care, 1994; 6(4): 353-359. 5. Smith RD, Jan S, Shiell A. Efficiency considerations in expanding radiation therapy services. International Journal of Radiation Oncology, Biology and Physics, 1995; 31(2): 379-386. 6. Smith RD. Is ‘Regret Theory’ an alternative basis for estimating the value of healthcare interventions? Health Policy, 1996; 37(2): 105-115. 7. Coast J, Smith RD, Millar MR. Super-Bugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Economics, 1996; 5(3): 217-226. 8. Wilton P, Smith RD. Primary care reform: a three country comparison of ‘budget holding’. Health Policy, 1998; 44: 149-166. 9. Smith RD, Wilton P. General practice fundholding: progress to date. British Journal of General Practice, 1998; 48: 1253-1257. 10. Smith RD, Widiatmoko D. The cost-effectiveness of home assessment and modification to reduce falls in the elderly. Australian and New Zealand Journal of Public Health, 1998; 22(4): 436-440. 11. Smith RD, Coast J. Controlling antimicrobial resistance: a proposed transferable permit market. Health Policy, 1998; 43(3): 219-232. 12. Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. Social Science and Medicine, 1998; 46(1): 29-38. 13. Wilton P, Smith RD. Budget-holding: the answer to Australian primary care reform? Australian Health Review, 1999; 22(3): 78-94. 14. Smith RD. The discrete choice willingness-to-pay question format in Health Economics: should we adopt environmental guidelines? Medical Decision Making, 2000; 20(2): 194- 206. 15. Smith RD. Promoting the health of people with physical disabilities: a discussion of the financing and organisation of public health services in Australia. Health Promotion International, 2000; 15(1): 79-86. 16. Wilton P, Smith RD, Coast J, Millar M, Karcher A. Directly observed therapy for multi- drug resistance tuberculosis: an economic evaluation in the United States of America and South Africa. The International Journal of Tuberculosis and Lung Disease, 2001; 5: 1137-1142. 17. Smith RD, Fordham R. The economics of fall prevention programmes: evidence and research priorities. Expert Review of Pharmacoeconomics & Outcomes Research, 2001; 1: 59-67 (invited paper).
14 18. Smith RD. The relative sensitivity of willingness-to-pay and time-trade-off to changes in health status: an empirical investigation. Health Economics, 2001; 10: 487-497. 19. Coast J, Smith RD. Antimicrobial resistance: can economics help? Eurohealth, 2001; 7(2): 32-33 (invited paper). 20. Olsen JA, Smith RD. Theory versus practice: A review of ‘willingness-to-pay’ in health and health care. Health Economics, 2001; 10(1): 39-52. 21. Coast J, Smith RD. Economics of antimicrobial resistance: a brief review. Journal of Drug Assessment, 2002; 5: 3-10 (invited paper). 22. Coast J, Smith RD, Karcher AM, Wilton P, Millar M. Superbugs II: How should economic evaluation be conducted for interventions which aim to reduce antimicrobial resistance? Health Economics, 2002; 11(7): 637-647. 23. Wilton P, Smith RD, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. Journal of Health Services Research and Policy, 2002; 7(2): 111-117. 24. Wilton P, Smith RD. Devolved budgetary responsibility in primary care: a cross-country assessment of the impact on efficiency. The European Journal of Health Economics, 2002; 3(1): 17-25. 25. Smith RD, Coast J. Antimicrobial resistance: a global response. Bulletin of the World Health Organisation, 2002; 80: 126-133. 26. Smith RD. Construction of the contingent valuation market in health care: a critical assessment. Health Economics, 2003; 12(8): 609-628. 27. Coast J, Smith RD. Antimicrobial resistance: cost and containment. Expert Review of Anti-infective Therapy, 2003; 1(2): 241-251 (invited paper). 28. Thorsteinsdóttir H, Daar A, Smith RD, Singer P. Genomics - A Global Public Good? The Lancet, 2003; 361: 891-892. 29. Smith RD, Coast J. Resisting resistance: thinking strategically about antimicrobial resistance. Georgetown Journal of International Affairs, 2003; IV(1): 135-141 (invited paper). 30. Yeung RYT, Smith RD, McGhee SM. Willingness to pay and size of health benefit: an integrated model to test for ‘sensitivity to scale’ Health Economics, 2003; 12(9): 791- 796. 31. Richardson J, Smith RD. Calculating society’s willingness-to-pay for a QALY: key questions for discussion. Applied Health Economics and Health Policy, 2004; 3 (3): 125- 126. 32. Smith RD. The reliability of willingness to pay for changes in health status. Applied Health Economics and Health Policy, 2004; 3(1): 35-38. 33. Smith RD. Foreign direct investment and trade in health services: a review of the literature. Social Science and Medicine, 2004; 59: 2313-2323. 34. Holland R, Smith RD, Harvey I, Lenaghan E. Assessing quality of life in the elderly: a comparison of two utility measures. Health Economics, 2004; 13(8): 793-806. 35. Smith RD, Woodward D, Acharya A, Beaglehole R, Drager N. Communicable Disease Control: a ‘Global Public Good’ perspective. Health Policy and Planning, 2004; 19(5): 271-278. (Also reprinted in: Kirton J (ed), Global Health, Ashgate, April 2009; Chapter 13: pp 191-198). 36. Smith RD, Thorsteinsdóttir H, Daar A, Gold R, Singer P. Genomics knowledge and equity: a global public good’s perspective of the patent system. Bulletin of the World Health Organization, 2004; 82(5): 385-389. 37. Raithatha N, Smith RD. Paying for statins. British Medical Journal, 2004; 328: 400- 402. 38. Raithatha N, Smith RD. Disclosure of genetic tests for health insurance: is it ethical not to? The Lancet, 2004; 363: 395-396. 39. Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy, 2005; 74: 77-84.
15 40. Smith RD. Sensitivity to scale in contingent valuation: the importance of the budget constraint. Journal of Health Economics, 2005; 24: 515-529. 41. Holland R, Lenaghan E, Harvey I, Smith RD, Shepstone L, Lipp A, Christou M, Evans D, Hand C. Does home-based medication review keep older people out of hospital? The HOMER randomised controlled trial. British Medical Journal, 2005; 330: 293-295. 42. Smith RD, Yago M, Millar M, Coast J. Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. Journal of Health Economics, 2005; 24: 1055-1075. 43. Yeung RYT, Smith RD. Can we use contingent valuation to assess the private demand for childhood immunization in developing countries? A systematic review of the literature. Applied Health Economics and Health Policy, 2006; 4: 165-173. 44. Smith RD. Its not just what you do, its the way that you do it: the effect of different payment card formats and survey administration on willingness to pay for health gain. Health Economics, 2006; 15: 281-293. 45. Covey J, Smith RD. How common is the ‘prominence effect’? Additional evidence to Whynes et al. Health Economics, 2006; 15: 205-210. 46. Heller RF, Gemmell I, Wilson ECF, Fordham R, Smith RD. Using economic analyses for local priority setting: the population cost-impact approach. Applied Health Economics and Health Policy, 2006; 5: 45-54. 47. Smith RD, Yago M, Millar M, Coast J. A macro-economic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin-resistant staphylococcus aureus (MRSA). Applied Health Economics and Health Policy, 2006; 5: 55-65. 48. Smith RD, Raithatha N. Why disclosure of genetic tests for health insurance should be voluntary. Journal of Health Services Research and Policy, 2006; 11: 184-186. 49. Myint PK, Welch AA, Luben RN, Wainwright NWJ, Surtees PG, Bingham SA, Wareham NJ, Smith RD, Harvey IM, Khaw KT. Obesity indices and self-reported functional health in men and women in the EPIC-Norfolk. Obesity, 2006; 14: 884-893. 50. Holland R, Lenaghan E, Smith RD, Lipp A, Christou M, Evans D, Harvey I. Delivering a home-based medication review, lessons from the HOMER randomised controlled trial. International Journal of Pharmacy Practice, 2006; 14: 71-79. 51. Yeung RYT, Smith RD, Ho LM, Johnston J, Leung G. Empirical implications of response acquiescence in discrete-choice contingent valuation. Health Economics, 2006; 15: 1077-1089. 52. Smith RD. Measuring the globalisation of health services: a possible index of openness of country health sectors to trade. Health Economics, Policy and Law, 2006; 1: 323-342. (see also: Hsiao WC. Reflecting on ‘Measuring the globalization of health services: a possible index of openness of country health sector to trade’. Health Economics, Policy and Law, 2015; 10: 393-398 doi:10.1017/S1744133115000110). 53. Smith RD. Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and management. Social Science and Medicine, 2006; 63: 3113-3123. 54. Barrett A, Roques T, Small M, Smith RD. How much will herceptin really cost? British Medical Journal, 2006; 333: 1118-1120. 55. Myint PK, Welch AA, Bingham SA, Surtees PG, Wainwright NWJ, Luben RN, Wareham NJ, Smith RD, Harvey I, Day NE, Khaw KT. Fruit and vegetable consumption and self- reported functional health in men and women in the European Prospective Investigation into Cancer –Norfolk (EPIC-Norfolk): a population based cross sectional study. Public Health Nutrition, 2006; 10(1): 34-41. 56. Smith RD. The relationship between reliability and size of willingness to pay values: a qualitative insight. Health Economics, 2007; 16: 211-216.
16 57. Sach TH, Smith RD, Whynes DK. A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow? PharmacoEconomics, 2007; 25: 107-127. 58. Pacini M, Smith RD, Wilson E, Holland R. Home based medication review in older people: is it cost-effective? Pharmacoeconomics, 2007; 25: 171-180. 59. Myint PK, Surtees PG, Wainwright NWJ, Wareham NJ, Bingham SA, Luben RN, Welch AA, Smith RD, Harvey IM, Khaw KT. Modifiable lifestyle behaviors and functional health in the European Prospective Investigation into Cancer (EPIC)–Norfolk population study. Preventive Medicine, 2007; 44: 109-116. 60. Holland R, Brooksby I, Lenaghan E, Ashton K, Hay L, Smith RD, Shepstone L, Lipp A, Daly C, Howe A. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. British Medical Journal, 2007;334: 1098-1100. 61. Myint PK, Luben RN, Surtees PG, Wainwright NWJ, Welch AA, Bingham SA, Wareham NJ, Smith RD, Harvey I, Khaw KT. Self-reported mental health-related quality of life and mortality in men and women in the European Prospective Investigation into Cancer (EPIC- Norfolk): a prospective population study. Psychosomatic Medicine, 2007; 69: 410-414. 62. Smith RD. Use, option and externality values: are contingent valuation studies in health care mis-specified? Health Economics, 2007; 16: 861-869. 63. Sadique MZ, Edmunds WJ, Smith RD, Meerding WJ, de Zwart O, Brug J, Beutels P. Don’t panic! A multi-country population-based survey of precautionary behaviour in response to the perceived threat of pandemic influenza. Emerging Infectious Disease, 2007; 13: 1307-1313. 64. Whynes D, Frew E, Philips Z, Covey J, Smith RD. The ‘prominence effect’ on contingent valuation. Journal of Economic Psychology, 2007; 28: 462-476. 65. Smith RD, MacKellar L. Global Public Goods and the Global Health Agenda: Problems, Priorities and Potential. Globalization and Health, 2007, 3:9 (invited paper). doi:10.1186/1744-8603-3-9. http://www.globalizationandhealth.com/content/3/1/9 66. Smith RD. The role of ‘reference goods’ in contingent valuation: should we help respondents to ‘construct’ their willingness to pay? Health Economics, 2007; 16: 1319- 1332. 67. Smith RD. Contingent valuation in health care: does it matter how the ‘good’ is described? Health Economics, 2008; 17:607-617. 68. Coast J, Smith RD, Lorgelly P. The influence of capabilities on health care decision making in the UK. Social Science and Medicine, 2008; 67: 1190-1198. 69. Baker R, Robinson A, Smith RD. How do respondents explain WTP responses? A review of the qualitative evidence. Journal of Socio-Economics, 2008; 37: 1427-1442. 70. Keogh-Brown M, Smith RD. The economic impact of SARS: how does the reality match the predictions. Health Policy, 2008; 88: 110-120. 71. Beutels P, Edmunds WJ, Smith RD. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. Health Economics, 2008; 17: 1317-1322. 72. Smith RD, Chanda R, Tangcharoensathien V. Trade in health-related services. The Lancet, 2009; 373: 593-601 (invited paper). 73. Smith RD, Correa C, Oh C. Trade, TRIPS, and pharmaceuticals. The Lancet, 2009; 373: 684-691 (invited paper). 74. Smith RD, Lee K. Trade and health: an agenda for action. The Lancet, 2009; 373: 768- 773 (invited paper). 75. Beutels P, Jia N, Zhou Q, Smith RD, Cao W, de Vlas S. The economic impact of Severe Acute Respiratory Syndrome (SARS) in Beijing, China. Tropical Medicine and International Health, 2009; 14: 85-91.
17 76. Smith RD, Keogh-Brown M, Barnett A, Tait J. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. British Medical Journal, 2009; 339: b4571 (also, 7733: 1298). 77. Keogh-Brown M, Smith RD, Edmunds JW, Beutels P. The Macroeconomic Impact Of Pandemic Influenza: Estimates From Models Of The UK, France, Belgium And The Netherlands. The European Journal of Health Economics, 2010; 11: 543-554. 78. Smith RD, Sach TH. Contingent valuation: what needs to be done. Health Economics, Policy and Law, 2010; 5: 91–111 (invited paper). 79. Smith RD, Sach TH. Contingent valuation: has the debate begun? Health Economics, Policy and Law, 2010; 5: 133–134 (invited response). 80. Smith RD, Petticrew M. Public health evaluation in the 21st century: time to see the wood as well as the trees. Journal of Public Health, 2010; 32: 2-7. 81. Smith RD. The role of economic power in influencing the development of global health governance. Global Health Governance, 2010; Volume III, Number 2 (Spring) http://www.ghgj.org. 82. Keogh-Brown M, Wren-Lewis S, Edmunds WJ, Beutels P, Smith RD. The possible macroeconomic impact on the UK of an influenza pandemic. Health Economics, 2010; 19: 1345-1360. 83. Lock K, Smith RD, Dangour A, Keogh-Brown M, Pigatto G, Hawkes C, Fisjberg R, Chalabi Z. Health, Agricultural and Economic Effects of Adopting Healthy Diet Recommendations. The Lancet, 2010; 376: 1699-1709 (invited paper). 84. Myint PK, Smith RD, Luben RN, Surtees PG, Wainwright NWJ, Wareham NJ, Bingham SA, Khaw KT. The Short-Form Six-Dimension (SF-6D) utility index predicted mortality in the EPIC-Norfolk prospective population-based study. Journal of Clinical Epidemiology, 2010; 63(2):192-198. 85. Myint PK, Smith RD, Luben RN, Surtees PG, Wainwright NWJ, Wareham NJ, Bingham SA, Khaw KT. Lifestyle behaviours and quality-adjusted life years in middle and older age. Age and Ageing, 2011; 40(5):589-595. 86. Oppong R, Coast J, Hood K, Nuttall J, Smith RD, Butler CC. Resource use and costs of treating lower respiratory tract infections in thirteen European countries: results and challenges. The European Journal of Health Economics, 2011; 12: 319-329. 87. Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J, Bateman I, Loomes G, Robinson R, Sugden R, Pinto-Prades JL, Ryan M, Shackley P, Smith RD. The social value of a QALY: raising the bar or barring the raise? BMC Health Services Research, 2011; 11:8 (http://www.biomedcentral.com/1472-6963/11/8). 88. Martínez Álvarez M, Chanda R, Smith RD. The potential for bi-lateral agreements in medical tourism: A qualitative study of stakeholder perspectives from the UK and India. Globalization and Health, 2011, 7:11. doi:10.1186/1744-8603-7-11. (http://www.globalizationandhealth.com/content/pdf/1744-8603-7-11.pdf) 89. Hargreaves JR, Greenwood B, Clift C, Goel A, Roemer-Mahler A, Smith RD, Heymann DL. Making new vaccines affordable: a comparison between the processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines. The Lancet 2011; 377 DOI:10.1016/S0140-6736(11)60687-9. 90. Smith RD, Keogh-Brown M, Barnett A. Estimating the economic impact of pandemic influenza: an application of the computable general equilibrium model to the UK. Social Science and Medicine, 2011; 73: 235-244. 91. Smith RD, Martinez-Alvarez M, Chanda R. Medical tourism: a review of the literature and analysis of a role for bi-lateral trade. Health Policy, 2011; 103: 276-282. 92. Lee K, Smith RD. What is Global Health Diplomacy? A conceptual review. Global Health Governance, 2011; Volume V, Number 1 (Fall) http://www.ghgj.org. 93. Oppong R, Kaambwa B, Nuttal J, Hood K, Smith RD, Coast J. Assessment of the construct validity of the EQ-5D in patients with acute cough/LRTI. Applied Research in Quality of Life, 2011; 6: 411–423.
18 94. Oppong R, Kaambwa B, Nuttall J, Hood K, Smith RD, Coast J, The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/ lower respiratory tract infections in seven countries. European Journal of Health Economics, 2011; DOI: 10.1007/s10198-011-0360-9. 95. Smith RD. Why a macro-economic perspective is critical to the prevention of non- communicable disease. Science, 2012; 337: 1501-1503 (www.sciencemag.org/cgi/content/short/337/6101/1501) 96. Yamabhai I, Smith RD. A review of the health and economic implications of patent protection, with a specific focus on Thailand. Health Research Policy and Systems, 2012; 10:24. DOI: 10.1186/1478-4505-10-24 (www.health-policy-systems.com/content/10/1/24) 97. Smith RD, Lagarde M, Blaauw D, Goodman C, English M, Mullei K, Pagaiya N, Tangcharoensathien V, Erasmus E, Hanson K. Appealing to altruism: an alternative strategy to address the health workforce crisis in developing countries? Journal of Public Health, 2012; doi: 10.1093/pubmed/fds066 98. Smith RD, Coast J. Antimicrobial resistance: the true cost. British Medical Journal, 2013; 346: 20-22 (BMJ 2013;346:f1493) (plus associated Editor’s Choice, Editorial, and BMJ Poll). 99. Rassy D, Smith RD. The Economic Impact of H1N1 on Mexico’s Tourist and Pork Sectors. Health Economics, 2013; 22: 824-834. 100. Green R, Cornelsen L, Turner R, Dangour AD, Shankar B, Mazzocchi M, RD Smith. The effect of rising food prices on food consumption: systematic review with meta- regression. British Medical Journal, 2013; 346:f3703 doi: 10.1136/bmj.f3703 (347: 13 print summary). 101. Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Molstad S, Coast J. Cost- effectiveness of point of care c-reactive protein testing to inform antibiotic prescribing decisions. British Journal of General Practice, 2013; doi: 10.3399/bjgp13x669185 (63: 357-358 print summary) 102. Tusting LS, Willey B, Lucas H, Thompson J, Kafy HT, Smith RD, Lindsay SW. Socioeconomic development as an intervention against malaria: a systematic review and meta-analysis. The Lancet, 2013; 382:963-972 (and associated commentary: 920-922) 103. Hanefeld J, Smith RD, Lunt N, Horsfall D, King H. Medical tourism: a cost or benefit to the NHS? PLoS ONE, 2013: 8, e70406 (DOI 10.1371/journal.pone.0070406). See also associated feature in BMJ (BMJ 2013;347:f6444) and editorial in the Lancet (vol 382; p1459) 104. Yamabhai I, Smith RD. Balancing the right to know with the privacy of the patent system: a case study of oncology medicines in Thailand. International Journal of Intellectual Property Management, 2013; 6: 272-284. 105. Smith RD, Keogh-Brown MR. Macroeconomic impact of a mild influenza pandemic and associated policies in Thailand, South Africa and Uganda: a computable general equilibrium analysis. Influenza and Other Respiratory Viruses, 2013; 7: 1400–1408. 106. Liverani M, Waage J, Rudge J, Barnett A, Pfeiffer D, Rushton J, Scoones I, Smith RD, Cooper B, White L, Goh S, Horby P, Wren B, Gundogdu O, Woods A, Coker R. Understanding and Managing Zoonotic Risk in the new Livestock Industries. Environmental Health Perspectives, 2013; 121: 873-877. 107. Jensen HT, Keogh-Brown M, Smith RD, Chalabi Z, Dangour A, Edwards P, Garnett T, Givoni M, Griffiths U, Hamilton I, Roberts I, Wilkinson P, Woodcock J, Haines A. The importance of health co-benefits in macroeconomic assessments of UK Greenhouse Gas emission reduction strategies. Climatic Change, 2013; 121: 223–237. 108. Lunt N, Horsfall D, Smith RD, Exworthy M, Hanefeld J, Mannion R. Market size, market share and market strategy: three myths of medical tourism. Policy & Politics, 2014; 42: 597-614 (http://dx.doi.org/10.1332/030557312X655918)
19 109. Marten R, Hanefeld J, Smith RD. Power: The nexus of global health diplomacy. Journal of Health Diplomacy online (18 March 2014): http://www.ghd- net.org/sites/default/files/marten%20hanefeld%20smith_power%20(1).pdf. 110. Lunt N, Smith RD, Mannion R, Green ST, Exworthy M, Hanefeld J, et al. Implications for the NHS of inward and outward medical tourism: a policy and economic analysis using literature review and mixed-methods approaches. Health Services and Delivery Research, 2014; 2(2) (DOI: 10.3310/hsdr02020). Available at http://www.journalslibrary.nihr.ac.uk/hsdr/volume-2/issue-2. 111. Noree T, Smith RD, Hanefeld J. UK medical tourists in Thailand - they are not who you think they are. Globalisation and Health, 2014; 10: 29 (doi:10.1186/1744-8603-10- 29). 112. Thaiprayoon S, Smith RD. Capacity building for Global Health Diplomacy: Thailand’s experience of trade and health. Health Policy and Planning, 2014; doi: 10.1093/heapol/czu117. 113. Baker R, Wildman J, Mason H, Donaldson C (on behalf of SVQ Team: Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Pinto-Prades JL, Robinson A, Ryan M, Shackley P, Smith RD, Sproston K, Sugden R, Wardle H, Wildman J. Q-ing for health—a new approach to eliciting the public's views on health care resource allocation. Health Economics, 2014; 23: 283–297 (doi:10.1002/hec.2914). 114. Hanefeld J, Smith RD, Lunt N, Horsfall D. What do we know about medical tourism? A review of the literature with discussion of its implications for the UK NHS as an example of a public health care system. Journal of Travel Medicine 2014; 21: 410- 417. 115. Cornelson L, Green R, Dangour A, Smith RD. Why fat taxes won’t make us thin. Journal of Public Health, 2015; 37(1): 18-23 (doi:10.1093/pubmed/fdu032). 116. Lunt N, Exworthy M, Hanefeld J, Smith RD. International patients within the NHS: a case of public sector entrepreneurialism. Social Science and Medicine, 2015; 124: 338- 345. 117. Hanefeld J, Lunt N, Horsfall D, Smith RD. Why do medical tourists travel to where they do? The role of networks in determining medical travel. Social Science and Medicine, 2015; 124: 356-363. 118. Kinghorn P, Robinson A, Smith RD. Developing a Capability-Based Questionnaire for Assessing Well-Being in Patients with Chronic Pain. Social Indicators Research, 2015; 120: 897-916. 119. Walls H, Smith RD, Drahos P. Improving the regulatory capacity of developing countries to manage risks associated with trade agreements. Globalization and Health, 2015: 11; 14 (doi:10.1186/s12992-015-0099-7). 120. Yamabhai I, Smith RD. To what extent are pharmaceutical prices determined by patents? A case study of oncology medicines in Thailand. Journal of Intellectual Property Rights, 2015; 20: 89-95. 121. Quilici S, Smith RD, Signorelli C. The role of vaccination in economic growth. Journal of Market Access & Health Policy 2015, 3: 29204 - http://dx.doi.org/10.3402/jmahp.v3.29204. 122. Cornelsen L, Green R, Turner R, Dangour AD, Shankar B, Mazzocchi M, RD Smith. What happens to patterns of food consumption when food prices change? Evidence from a systematic review and meta-analysis of food price elasticities globally. Health Economics, 2015; 24: 1548-1559. 123. Hordijk PM, Broekhuizen BDL, Butler CC, Coast J, Coenen S, Godycki-Cwirko M, Goossens H, Hood K, Smith RD, van Vugt SF, Little P, Verheij TJM. Illness perception and behaviour in lower respiratory tract infections: A European study. Family Practice, 2015; 32 (2): 152-158. 124. Walls H, Baker P, Smith RD. Moving towards policy coherence in health and trade. Journal of Public Health Policy, 2015; 36(4):491-501.
20 125. Shemilt I, Marteau TM, Smith RD, Ogilvie D. Use and cumulation of evidence from modelling studies to inform policy on food taxes and subsidies: biting off more than we can chew? BMC Public Health, 2015; 15: 297 DOI 10.1186/s12889-015-1641-5. 126. Coast J, Smith RD. Distributional considerations in economic responses to antimicrobial resistance. Public Health Ethics, 2015; 8 (3): 225-237. 127. Noree T, Hanefeld J, Smith RD. Medical Tourism in Thailand: a cross-sectional study. The Bulletin of the World Health Organization, 2016; 94: 30–36 (doi: http://dx.doi.org/10.2471/BLT.14.152165). 128. Årdal C, Outterson K, Hoffman S, Ghafur A, Sharland M, Ranganathan N, Smith RD, Zorzet A, Cohn J, Pittet D, Daulaire N, Morel C, Rizvi Z, Balasegaram M, Dar O, Heymann D, Holmes A, Moore L, Laxminarayan R, Mendelson M, Røttingen JA. International cooperation to improve access to and sustain effectiveness of antimicrobials. The Lancet, 2016; 387: 296-307. 129. Keogh-Brown M, Jensen, HJ, Arrighi M, Smith RD. The impact of Alzheimer’s Disease on the Chinese economy. EBiomedicine, 2016; 4: 184-190. 130. Sheppard P, Smith RD. What students want: using a choice modelling approach to estimate student demand. Journal of Higher Education Policy and Management, 2016; DOI: 10.1080/1360080X.2016.1150236. 131. Walls H, Cornelsen L, Lock K, Smith RD. How much priority is given to nutrition and health in the EU Common Agricultural Policy? Food Policy, 2016; 59: 12–23 (http://dx.doi.org/10.1016/j.foodpol.2015.12.008). 132. Smith RD, Irwin R. Measuring success in global health diplomacy: lessons from marketing food to children in India. Globalization and Health, 2016; 12:28 (DOI: 10.1186/s12992-016-0169-5) (http://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-016-0169-5). 133. Oppong R, Smith RD, Little P, Verheij T, Butler CC, Goosens H, Coenen S, Moore M, Coast J. Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. British Journal of General Practice 2016; 66 (650): e633-e639. DOI: https://doi.org/10.3399/bjgp16X686533. 134. Cornelsen L, Green R, Dangour AD, Mazzocchi M, RD Smith. Estimating the relationship between food prices and food consumption – methods matter. Applied Economic Perspectives and Policy, 2016; 38 (3): 546-561. 135. Walls HL, Kadiyala S, Smith RD. Research and policy for addressing malnutrition in all its forms. Obes Silver Spring Md. 2016; 24(10): 2032–2032. 136. White M, Rayner M, Smith RD, et al. Protocol - Evaluation of the health impacts of the UK Treasury Soft Drinks Industry Levy (SDIL). NIHR Journals Library 2017; https://www.journalslibrary.nihr.ac.uk/programmes/phr/1613001/#/. 137. Shankar B, Thaiprasert N, Gheewala S, Smith RD. Policies for healthy and sustainable edible oil consumption: a stakeholder analysis for Thailand. Public Health Nutrition, 2017; 20(6):1126-1134. doi: 10.1017/S1368980016003037. 138. Hanefeld J, Khan M, Tomson G, Smith RD. Trade is central to achieving the Sustainable Development Goals: a case-study of antimicrobial resistance. British Medical Journal, 2017; 358: j3505 doi: 10.1136/bmj.j3505. 139. Cornelsen L, Mytton O, Adams J, Gasparrini A, Iskander D, Knai C, Petticrew M, Scott C, Smith R, Thompson C, White M, Cummins S. Change in non-alcoholic beverage sales following a 10-pence levy on sugar-sweetened beverages within a national chain of restaurants in the UK: interrupted time series analysis of a natural experiment. Journal of Epidemiology and Community Health, 2017; 71: 1107–1112. doi 10.1136/jech-2017-209947 140. Tuomisto HL, Scheelbeek PFD, Chalabi Z, Green R, Smith RD, Haines A, Dangour AD. Effects of environmental change on population nutrition and health: a comprehensive
21 framework with a focus on fruits and vegetables. Wellcome Open Research, 2017; 2:21 (doi: 10.12688/wellcomeopenres.11190.2). 141. Kabajulizi J, Keogh-Brown MK, Smith RD. The welfare implications of public healthcare financing: a macro–micro simulation analysis of Uganda. Health Policy and Planning, 2017; 32: 1437-1448 (doi: 10.1093/heapol/czx12). 142. Cornelsen L, Smith RD. Soda taxes – four questions economists need to address. Food Policy, 2018; 74: 138-142 (https://doi.org/10.1016/j.foodpol.2017.12.003). 143. Quirmbach D, Cornelsen L, Jebb S, Marteau T, Smith RD. Effect of increasing the price of sugar-sweetened beverages on alcoholic beverage purchases: an economic analysis of sales data. Journal of Epidemiology and Community Health, 2018; 72: 324– 330 (http://dx.doi.org/10.1136/jech-2017-209791). 144. Suzana M, Walls H, Smith RD, Hanefeld J. Achieving universal health coverage in small island states: could importing health services provide a solution? BMJ Global Health, 2018: DOI: 10.1136/bmjgh-2017-000612 Published 19 February 2018. 145. Smith RD, Cornelsen L, Quirmbach D, Jebb S, Marteau T. Reducing sugar consumption: are sweet snacks more sensitive to price increases than sugar-sweetened beverages? BMJ Open 2018;8:e019788. doi:10.1136/bmjopen-2017-019788. 146. Irwin R, Smith RD. Rituals of global health: negotiating the World Health Assembly. Global Public Health, 2018: https://doi.org/10.1080/17441692.2018.1504104. 147. Suzana M, Walls H, Smith RD, Hanefeld J. Evaluation of public subsidy for medical travel: does it protect against household impoverishment? International Journal for Equity in Health (in press). 148. Walls HL, Johnston D, Tak M, Dixon J, Hanefeld J, Hull L, Smith RD. The impact of agricultural input subsidies on food and nutrition security: A systematic review. Food Security, 2018; 10:1425–1436 (https://doi.org/10.1007/s12571-018-0857-5). 149. Suzana M, Walls H, Smith RD, Hanefeld J. Understanding medical travel from a source country perspective: the experiences of medical travellers from the Maldives. Globalization and Health, 2018; 14:58 (https://doi.org/10.1186/s12992-018-0375-4). 150. Oppong R, Smith RD, Little P, Verheij T, Butler CC, Goossens H, Coen S, Jowett S, Roberts TE, Achana F, Stuart B, Coast J. Cost-effectiveness of internet-based training for primary care clinicians on antibiotic prescribing for acute respiratory-tract infections in Europe. Journal of Antimicrobial Chemotherapy, 2018;73(11): 3189-3198 (https://doi.org/10.1093/jac/dky309) 151. Cuevas S, Cornselsen L, Smith RD, Walls H. Economic globalization, nutrition and health: a review of quantitative evidence. Globalization and Health, 2019; 15:15 (https://doi.org/10.1186/s12992-019-0456-z). 152. Kadandale S, Marten R, Smith RD. The palm oil industry: An overlooked player in the NCD agenda? WHO Bulletin 2019; 97: 118–128 (http://dx.doi.org/10.2471/BLT.18.220434). 153. Jensen HT, Keogh-Brown M, Shankar B, Basu S, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Thaiprasert N, Smith RD. Palm oil and dietary change: Application of an integrated macroeconomic, environmental, demographic, and health modelling framework for Thailand. Food Policy, 2019; 83: 92-103 (https://doi.org/10.1016/j.foodpol.2018.12.003). 154. Roope LSJ, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibichg P, Butler C, Tan PS, Walker S, Robotham JV, Wordsworth S. The challenge of Antimicrobial Resistance: What can economics contribute? Science, 2019; 364 (DOI: 10.1126/science.aau4679). 155. Cornelsen L, Mazzocchi M, Smith RD. Fat tax or thin subsidy? How price increases and decreases affect the energy and nutrient content of food and beverage purchases in Great Britain. Social Science & Medicine, 2019; (https://doi.org/10.1016/j.socscimed.2019.04.003). 156. Hanefeld J, Smith RD. The upside of trade in health services. BMJ, 2019;365:l2208 doi: 10.1136/bmj.l2208.
22 157. Walls H, Smith RD, Cuevas S, Hanefeld J. International trade and investment: still the foundation for tackling nutrition related non-communicable diseases in the era of Trump? BMJ, 2019; 365: l2217 doi: 10.1136/bmj.l2217. 158. Marten R, Hanefeld J, Smith RD. How states exerted power to create the Millennium Development Goals and how this shaped the global health agenda: lessons for the Sustainable Development Goals and the future of global health. Global Public Health, 2019; 14: 584-599. 159. Waage J, Smith RD, Shankar B, Dangour A, Lock K et al. Integrating agriculture and health research for development: LCIRAH as an interdisciplinary programme to address a global challenge. Global Challenges (in press/invited) DOI: 10.1002/gch2.201700104. 160. Cornelsen L, Berger N, Cummins S, Smith RD. Socio-economic patterning of expenditures on 'out-of-home' food and non-alcoholic beverages by product and place of purchase in Britain. Social Science and Medicine, 2019; https://www.sciencedirect.com/science/article/abs/pii/S0277953619303466?via%3Dihub. 161. Berger N, Cummins S, Smith RD, Cornelsen L. Recent trends in energy and nutrient content of take-home food and beverage purchases in Great Britain: An analysis of 225 million food and beverage purchases over 6 years. BMJ Nutrition, Prevention & Health (in press). 162. White M, Aguirre E, Finegood DT, Holmes C, Sacks G, Smith RD. What role should commercial food systems play in promoting health through better diet? British Medical Journal (in press – invited). 163. Scheelbeek P, Cornelsen L, Marteau TM, Jebb SA, Smith RD. Impact on the UK prevalence of obesity of a 20% price increase on high-sugar snacks: A modelling study. British Medical Journal (in press). 164. Jensen HT, Keogh-Brown M, Shankar B, Aekplakorn W, Basu S, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Rojroongwasinkul N, Thaiprasert N, Smith RD. The impact of land subsidy reform on dietary change and cardiovascular disease: a case-study of palm oil in Thailand. Population Health Metrics (in press). 165. Pifarré Coutrot I, Smith RD, Cornelsen L. Is the rise of crowdfunding for medical expenses in the UK symptomatic of systemic gaps in health and social care? Journal of Health Services Research and Policy (in press). 166. Smith RD, Keogh-Brown M, Chico MR, Bretscher M, Drakeley C, Jensen HT. Will more of the same achieve malaria elimination? Results from an integrated macroeconomic-epidemiological-demographic model. American Journal of Tropical Medicine & Hygiene (in press). 167. Watt T, Cornelsen L, Smith RD. Reducing consumption of unhealthy foods and beverages through banning price promotions: what is the evidence and would it work? Public Health Nutrition (in press). 168. Jensen HT, Keogh-Brown MR, Shankar B, Aekplakornd W, Basu S, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Rojroongwasinkul N, Thaiprasert N, Smith RD. Palm oil and dietary change: Application of an integrated macroeconomic, environmental, demographic, and health modelling framework for Thailand. Food Policy, 2019; 83: 92–103. 169. Jensen HT, Keogh-Brown M, Shankar B, Aekplakorn W, Basu S, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Rojroongwasinkul N, Thaiprasert N, Smith RD. Trade reform, dietary change, and cardiovascular disease health outcomes: import tariff reform using an integrated macroeconomic, environmental and health modelling framework for Thailand. Social Science & Medicine – Population Health (in press). 170. Keogh-Brown MR, Jensen HT, Basu S, Aekplakorn W, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Rojroongwasinkul N, Thaiprasert N, Shankar B, Smith RD. Evidence on the magnitude of the economic, health and population effects of palm cooking oil consumption: An integrated modelling approach with Thailand as a case
23 study. Population Health Metrics, 2019; 17:12 (https://doi.org/10.1186/s12963-019- 0191-y). 171. Smith RD, Keogh-Brown M, Chico M, Bretcher M, Bretscher M, Drakeley C, Jensen HT. Will more of the same achieve malaria elimination? Results from an integrated macroeconomic-epidemiological-demographic model. American Journal of Tropical Medicine & Hygiene (in press). 172. Yerushalmia E, Hunt P, Hoorens S, Sauboin C, Smith RD. Exploring the use of a general equilibrium method to assess the value of a malaria vaccine: an application to Ghana. Medical Decision Making Policy and Practice (in press).
Journal Special Series Editor The Lancet Series on “Trade and Health”, 2009 (co-editor with Lee, K) Social Science & Medicine Series on “Medical Tourism”, 2015 (co-editor with Hanefeld J, Lunt N) Antibiotics Special Issue on "Tackling Challenges Associated with Antimicrobial Resistance: The Policy and Economic Perspectives", 2019 (lead editor, with Coast J, Lanbert H, Hanefeld J). BMJ series on ‘trade and health’, 2019 (co-editor Hanefeld, J)
Editorials, letters, commentaries, book reviews etc 173. Smith RD, Hall J, Gurney HG, Harnett PR. A cost-utility approach to the use of 5- fluorouracil and levamisole as adjuvant chemotherapy for Dukes’ C colonic carcinoma: a reply. Medical Journal of Australia, 1993; 158(12): 866 (letter). 174. Smith RD, Scott A. The economic impact of chronic fatigue syndrome. Medical Journal of Australia, 1993; 158(4): 286 (letter). 175. Smith RD. Caution in using wages to assess community savings. Australian and New Zealand Journal of Medicine, 1993; 23(1): 56 (letter). 176. Smith RD, Coast J, Millar, MR. Over-the-counter antimicrobials: the hidden costs of resistance. Journal of Antimicrobial Chemotherapy, 1996; 37: 1031-1032 (letter). 177. Smith RD. Antimicrobial resistance: the importance of developing long term policy. Bulletin of the World Health Organisation, 1999; 77(10): 862 (letter). 178. Smith RD. Global public goods and health. Bulletin of the World Health Organization, 2003; 81(7): 475 (invited editorial). 179. Coast J, Smith RD. Solving the problem of antimicrobial resistance: is a global approach necessary? Drug Discovery Today, 2003; 8(1): 1-2 (editorial). 180. Holland R, Smith RD, Harvey I. Where now for pharmacist-led medication review? Journal of Epidemiology and Community Health, 2006; 60: 90-93 (editorial). 181. Smith RD. Trade and public health: facing the challenges of globalization. Journal of Epidemiology and Community Health, 2006; 60: 650-651 (invited editorial). 182. Smith RD. Globalization: the key challenge facing health economics in the 21st century. Health Economics, 2008; 17: 1–3 (invited editorial). 183. Coast J, Smith RD, Lorgelly P. Should the capability approach be applied in health economics? Health Economics, 2008; 17: 667-670 (invited editorial). 184. Smith RD, Sach T. Contingent Valuation: (still) on the road to nowhere? Health Economics, 2009; 18:863-866 (invited editorial). 185. Smith RD. Health and Development: toward a matrix approach. Bulletin of the World Health Organization, 2009; 87: 883-884 (invited book review). 186. Lorgelly P, Smith RD, Coast J. Concepts of capability and overlooked applications. American Journal of Public Health, 2010: 100; 1823-1824 (letter). 187. Smith RD. Intellectual Property, Medicine and Health: current debates. European Journal of Public Health, 2010; 20: 236–237 (invited book review). 188. Smith RD, Lunt N, Hanefeld J. The implications of PIP are more than just cosmetic. The Lancet, 2012: DOI:10.1016/S0140-6736(12)60166-4 (comment). 24 189. Smith RD. Online marketing of medical procedures needs better regulation. British Medical Journal, 2012: 344:e1399 doi: 10.1136/bmj.e1399 (personal view). 190. Hanefeld J, Lunt N, Horsfall D, Smith RD. Discussion on ban of advertising for cosmetic surgery needs to consider medical tourists. British Medical Journal, 2012: 345: http://www.bmj.com/content/345/bmj.e7535/rr/615768 (letter). 191. Hanefeld J, Smith RD, Lunt N, Horsfall D. UK is a net exporter of patients. British Medical Journal, 2013: 346: 26 (letter). 192. Hanefeld J, Lunt N, Smith RD. Health tourism and the NHS: facts or fiction? The Lancet, 2013: 382: e2 (letter). 193. Ghinai I, Tun Win Hla T, Smith RD. Disease burden should not be the sole driver of infectious disease research. Lancet Infectious Diseases, 2013; 13: 653 (letter). 194. Hanefeld J, Lunt N, Smith RD. Paying for migrant healthcare. British Medical Journal, 2013;347:f6514 (editorial) (and Editor’s Choice - BMJ 2013;347:f6556). 195. Cornelsen L, Green R, Dangour AD, Smith RD. Is a tax on sugary drinks too bitter to swallow? British Medical Journal, 2013; 347:f7039 (letter). 196. Chalkidou K, Marten R, Cutler D, Culyer A, Smith RD, Teerawattananon Y, Cluzeau F, Li R, Sullivan R, Huang Y, Fan V, Glassman A, Dezhi Y, Gyansa-Lutterodt M, McPherson S, Gadelha C, Sundararaman T, Squires N, Daulaire N, Sadanandan R, Shiro K, Lemgruber A. Health technology assessment in universal health coverage. The Lancet, 2013; 382: e48-e49 (Comment). 197. Marten R, Hanefeld J, Smith RD. Commission on Global Governance for Health: What about power? The Lancet, 2014; 383: 2207 (Letter). See also response by Engebretsen & Heggen, 384: 664. 198. Hanefeld J, Smith RD. Charging for health tourism. British Medical Journal, 2014; 349: 1-38 (9 August): 37 (Blog of the week). 199. Smith RD. Antimicrobial resistance is a social problem requiring a social solution. British Medical Journal, 2015; 350:h1453, doi:10.1136/bmj.h1453 (Observation). 200. Walls H, Smith RD. Rethinking governance for trade and health. British Medical Journal, 2015;351:h3652 doi: 10.1136/bmj.h3652 (Published 25 July, pg 8) (invited editorial). 201. Lawrence H Summers et al. Economists' Declaration on Universal Health Coverage. The Lancet, 2015; 386: 2112–13 (DOI: 10.1016/S0140-6736(15)00242-1). 202. Mills A, Smith RD, Hanson K. Healthy equality. Times Higher Education, 2015, October 8 (letter). 203. Walls HL, Vearey J, Modisenyane M, Chetty-Makkan CM, Charalambous S, Smith RD, Hanefeld J. Understanding healthcare and population mobility in southern Africa: The case of South Africa. South African Medical Journal, 2016; 106(1): 14-15 (DOI:10.7196/SAMJ.2016.v106i1.10210) (invited editorial). 204. Quirmbach D, Cornelsen L, Smith RD. The rise of soft drinks—sugar is not the only concern. British Medical Journal, 2016; 5 August (Blog): http://blogs.bmj.com/bmj/2016/08/05/the-rise-of-soft-drinks-sugar-is-not-the-only- concern/. 205. Walls H, Kdiyala S, Smith RD. Research and policy for addressing malnutrition in all its forms. Obesity (invited commentary); 2016: doi:10.1002/oby.21636 (http://onlinelibrary.wiley.com/doi/10.1002/oby.21636/full) 206. Walls H, Hanefeld J, Smith RD. The Trans-Pacific Partnership: should we ‘fear the fear’? International Journal of Health Policy and Management, 2017; 6(6): 353-355 (invited commentary) doi 10.15171/ijhpm.2016.140 207. Smith RD, Lee K. Global Health Governance: we need innovation not renovation. BMJ Global Health 2017;2:e000275. doi:10.1136/-2016000275 (commentary). 208. Hanefeld J, Vearey J, Lunt N, Bell S, Blanchet K, Duclos D, Ghilardi L, Horsfall D, Howard N, Adams J, Kamndaya M, Lynch C, Makandwa T, McGrath N, Modesinyane M, O'Donnell K, Siriwardhana C, Smith RD, Testa A, Vanyoro K, Walls H, Wickramage
25 K, Zimmermann C. A global research agenda on migration, mobility, and health. The Lancet, 2017; 389: 2358-2359 (comment). 209. Hanefeld J, Mandeville K, Smith RD. Making “health tourists” pay for care: a pointless and damaging distraction from bigger problems in NHS. British Medical Journal, 2017;356:j771 doi: 10.1136/bmj.j771 (February 15) (editorial). 210. Marten R, Smith RD. State support: a prerequisite for global health network effectiveness. International Journal of Health Policy and Management, 2017; 6(x): x–x (invited commentary) doi:10.15171/ijhpm.2017.86. 211. Frew E, Ng SW, Coast J, Hollingsworth B, Smith RD. How can economics help tackle childhood obesity? Obesity, 2018; 26: 1112-1113 (Perspective) doi:10.1002/oby.22211. 212. Marten R, Kadandale S, Butler J, Aguayo V, Axelrod S, Buse K, Casswell S, Dain K, Glassman A, Heymann D, Kickbusch I, Marquez P, Nordström A, Peterson S, Ralston J, Rasanathan K, Reddy S, Smith RD, Soucat A, Sperkova K, Thompson F, Webb D. Sugar, Tobacco and Alcohol Taxes (STAX): Indispensable tools to achieve the Sustainable Development Goals. The Lancet, 2018; 391: 2400-2401 (http://dx.doi.org/10.1016/S0140-6736(18)31219-4) (commentary). 213. Marten R, Kadandale S, Nordström A, Smith RD. Shifting global health governance towards the sustainable development goals. WHO Bulletin 2018; 96: 798–798A [doi: http://dx.doi.org/10.2471/BLT.18.209668] (editorial).
Article submitted to a journal 214. McGill E, Er V, Penney T, Egan M, Whitehead M, Lock K, De Cuevas RA, Smith RD, Meier P, Savona N, Rutter H, Marks D, White M, de Vocht F, Cummins S, Popay J, Petticrew M. Evaluation of public health interventions from a complex systems perspective: a critical review of methods and findings. Millbank Quarterly (submitted). 215. Pell D, Penney TL, Mytton O, Briggs A, Cummins S, Rayner M, Rutter H, Scarborough P, Smith RD, White M, Adams J. Anticipatory changes in British household purchases of soft drinks associated with the announcement of the Soft Drinks Industry Levy: a controlled interrupted time series analysis. British Medical Journal (submitted). 216. Walls H, Johnston D, Chirwa E, Matita M, Mazalale J, Quaife M, Kamwanja T, Smith RD. Do agricultural input subsidies improve dietary diversity? A case study of Malawi. The Lancet (submitted). 217. Cornelsen L, Quaife M, Lagarde M, Smith RD. Framing and signaling effects of taxes on sugary beverages: A Discrete Choice Experiment among regular consumers with children in Great Britain. Journal of Health Economics (submitted). 218. Law C, Cornelsen L, Adams J, Penney T, Rutter H, White M, Smith RD. Market reaction to the UK Soft Drinks Industry Levy announcements: Event study analysis of soft drink companies quoted on the London Stock Exchange. Health Economics Letters (submitted). 219. Penney TL, Adams J, Briggs A, Cummins S, Mytton O, Rayner M, Rutter H, Scarborough P, Smith RD, White M. How might the UK Soft Drinks Industry Levy influence sugar consumption and population health in the UK? Potential policy impacts and implications for evaluation. PLoSMed (submitted). 220. Egan M, McGill E, Penney T, Meier PS, Savona N, de Vocht F, Popay J, Cummins S, Smith RD, White M, Er V, Petticrew M. Evaluations of public health interventions using a complex systems lens: a critical review. The Lancet (submitted). 221. Oppong R, Brovall S, Henriques-Normark B, Verheij T, Ieven G, Goosens H, Smith RD, Coast J. Estimating costs associated with resistance: s.pneumoniae in acute cough/lower respiratory tract infection patients. Journal of Antimicrobial Chemotherapy (to be submitted).
26 222. Kabajulizi J, Keogh-Brown MK, Smith RD. The macroeconomic implications of public healthcare financing: a computable general equilibrium analysis of Uganda. Journal of Development Economics (submitted). 223. Jensen HT, Keogh-Brown M, Chico M, Bretcher M, Drakeley C, Gething P, Smith RD. Assessment of the Health and Economic Double-burden of Malaria: The Case of Ghana. Journal of Development Economics (submitted). 224. Hanefeld J, Walls H, Vearey J, Modisenyane M, Lunt N, Smith RD. Governance of trade in health services – an analysis of issues addressed in bilateral health agreements between South Africa and neighbouring countries. To be submitted. 225. Cornelsen L, Mazzocchi M, Smith RD. Between preferences and references: Evidence from Great Britain on asymmetric price elasticities. Journal of Economic Behaviour and Organization (submitted). 226. Chetty-Makkan C, Charalambous S, Walls H, Vearey J, Smith RD, Hanefeld J. Using facility-level health data for assessing the health and system impact of medical travel and migration: findings from a study of South Africa. To be submitted. 227. Hanefeld J, Smith RD, Drager N, Walls H. Trump and Brexit: A new era for trade and health? To be submitted. 228. Carriedo A, Koon A, Lee K, Ooms G, Silva D, Smith J, Smith RD, Walls H (alphabetical authorship). Political economy of sugar sweetened beverages: Perspectives on taxation in Latin America. WHO Bulletin (submitted).
Conference contributions 1. Jan S, Smith RD, Shiell A. Issues involved with employing ‘willingness to pay’ in road safety. In: C. Selby-Smith (Ed.) Economics and Health: 1993. Monash University, Victoria, Australia; 1993: 105-118. 2. Dobson M, Smith RD, Hall J. Do personal factors influence QALYs? In: Choice and change: the ethics, politics and economics of Public Health in Australia. Public Health Association of Australia, ACT, Australia; 1993: 224-230. 3. Smith RD, Coast J. Production externalities in healthcare: the case of antibiotic resistance. In: A. Harris (Ed.) Economics and Health: 1996. University of New South Wales, Sydney, Australia; 1997: 281-294. 4. Smith RD, Coast J. Controlling antibiotic resistance: further developments in the transferable permit market. In: A. Harris (Ed.) Economics and Health: 1997. University of New South Wales, Sydney, Australia; 1998: 155-169. 5. Wilton P, Smith RD. GP budget holding: bullseye or target miss? In: A. Harris (Ed.) Economics and Health: 1998. University of New South Wales, Sydney, Australia; 1997: 271-290. 6. Wilton P, Smith RD. General Practice Reform: an econometric assessment of the impact of patient enrolment and budget-holding. In: J. Baldry (Ed.) Economics and Health: 1999. University of New South Wales, Sydney, Australia; 2000: 273-297.
Other Sydney University (CHERE) Discussion Papers 1. Smith RD, Shiell A (1992). Economic evaluation and road safety programmes: the way forward? Discussion Paper No. 7. 2. Smith RD, Hall J (1993). The cost of operating the renal/pancreas transplant unit as a nationally funded centre. Discussion Paper No. 13. 3. Smith RD, Jan S, Shiell A (1993). Efficiency in the expansion of radiotherapy services. Discussion Paper No. 14. 4. Smith RD, Hall J, Harnett PR, Gurney HG (1993). A preliminary cost utility analysis of adjuvant chemotherapy for resected colonic carcinoma. Discussion Paper No. 15. 5. Smith RD, Jan S, Shiell A (1993). What are Australians willing to pay for road safety? Discussion Paper No. 21.
27
Monash University (HEU) Working Papers 1. Widiatmoko D, Smith RD (1996). The cost effectiveness of home assessment and modification to reduce falls in the elderly: a decision-analytic modelling approach. Working Paper No. 60. 2. Smith RD, Coast J (1997). The transferable permit market: a solution to antibiotic resistance? Working Paper No. 61. 3. Smith RD (1997). Health promotion and the disabled: funding issues. Working Paper No. 62. 4. Wilton P, Smith RD (1997). General Practice Fund Holding: Scoring a bullseye or missing the target? Working Paper No. 69. 5. Smith RD (1997). Contingent valuation: indiscretion in the adoption of dichotomous choice question formats? Working Paper No. 74. 6. Wilton P, Smith RD (1997). General Practice Fund Holding for Australia: panacea or poison? Working Paper No. 75. 7. Olsen JA, Smith RD, Harris A (1999). Economic Theory and the Monetary Valuation of Health Care: an overview of the issues as applied to the economic evaluation of health care programs. Working Paper No. 82. 8. Olsen JA, Smith RD (1999). Who have been asked to value what? A review of 54 ‘willingness-to-pay’ surveys in healthcare. Working Paper No. 83. 9. Smith RD, Olsen JA, Harris A (1999). A Review of Methodological Issues in the Conduct of WTP Studies in Health Care I: Construction and specification of the contingent market. Working Paper No. 84. 10. Smith RD, Olsen JA, Harris A (1999). A Review of Methodological Issues in the Conduct of WTP Studies in Health Care II: Administration of a CV survey. Working Paper No. 85. 11. Smith RD, Olsen JA, Harris A (1999). A Review of Methodological Issues in the Conduct of WTP Studies in Health Care III: Issues in the analysis and interpretation of WTP data. Working Paper No. 86. 12. Smith RD, Olsen JA, Harris A (1999). Resource allocation decisions and the use of WTP as a valuation technique within economic evaluation: recommendations from a review of the literature. Working Paper No. 87. 13. Smith RD (1999). Exploring the relationship between TTO and WTP – an empirical investigation. Working Paper No. 88. 14. Richardson J, Olsen JA, Hawthorne G, Mortimer D, Smith RD (1999). The measurement and valuation of utility based quality of life: Recommendations from a review of the literature. Working Paper 96. 15. Richardson J, Olsen JA, Hawthorne G, Mortimer D, Smith RD (1999). The measurement and valuation of quality of life in economic evaluation: An introduction and overview of issues and options. Working Paper 97.
Other publicly available documents 1. Smith RD, Jan S, Shiell A (1992). Feasibility of using willingness to pay techniques in the valuation of road safety measures. Report to: Federal Office of Road Safety, Department of Transport and Communications, Canberra, ACT, Australia. 2. Smith RD, Jan S, Shiell A (1993). Can we assess what Australians are willing to pay for road safety? Report to: Federal Office of Road Safety, Department of Transport and Communications, Canberra, ACT, Australia. 3. Selley S, Harvey I, Adamson J, Frankel S, Smith RD (1996). Best-practice guidelines for elective surgery. Report to: Department of Health, London. 4. Smith RD, Olsen JA, Harris AH (1998). Valuing health outcomes in monetary terms: A literature review. Report to: Pharmaceutical Benefits Branch, Commonwealth Department of Health and Family Services, Canberra, Australia.
28 5. Richardson J, Olsen JA, Hawthorne G, Mortimer D, Smith RD (1998). The measurement and valuation of utility based quality of life. Report to: Pharmaceutical Benefits Branch, Commonwealth Department of Health and Family Services, Canberra, Australia. 6. Smith RD, Coast J (2001). Global Responses to the Growing Threat of Antimicrobial Resistance. Commission on Macroeconomics and Health, Working paper WG2:17, World Health Organisation, Geneva. 7. Smith RD, Coast J, Millar MR, Wilton P, Karcher A-M (2001). Interventions against anti-microbial resistance: a review of the literature and exploration of modelling cost- effectiveness. Report to: Global Forum for Health Research, World Health Organisation, Geneva. 8. Smith RD, Harrold E, Salter B (2001). PCG Health Economics and Policy Advice Function. Report to: Norfolk and Suffolk Education and Training Consortium, Norwich. 9. Tyler J, Smith RD (2002). The evaluation of prevention, carers and partnership projects: methodology development and scheme evaluation. Report to: Norfolk County Council, Department of Social Services, Norwich. 10. Yago M, Smith RD, Coast J, Millar MR (2003). Development of an economic model of antimicrobial resistance. Report to: The Nuffield Trust, London. 11. Mortimer D, Smith RD, Coast J, Millar MR, Mills A (2003). Development of an economic model of antimicrobial resistance. Report to: Department of Child and Adolescent Health and Development, World Health Organization. 12. Smith RD, Sommers T (2003). Assessing the economic impact of communicable disease outbreaks: the case of SARS. Globalization, Trade and Health Working Paper, Strategy Unit, Director General’s Office (STU/DGO), World Health Organization, Geneva. 13. Gobrecht J, Smith RD, Drager N (2003). Measuring Trade in Health Services. Globalization, Trade and Health Working Paper, Strategy Unit, Director General’s Office (STU/DGO), World Health Organization, Geneva. 14. Chanda R, Smith RD, Drager N (2003). General framework for country analysis. Globalization, Trade and Health Working Paper, Strategy Unit, Director General’s Office (STU/DGO), World Health Organization, Geneva. 15. Chanda R, Smith RD, Drager N (2003). A framework for country analysis of commercial presence. Globalization, Trade and Health Working Paper, Strategy Unit, Director General’s Office (STU/DGO), World Health Organization, Geneva. 16. Smith RD (2003). Trade in health services: commercial presence-foreign direct investment. Globalization, Trade and Health Working Paper, Strategy Unit, Director General’s Office (STU/DGO), World Health Organization, Geneva. 17. Bateman I, Loomes G, Mugford M, Robinson A, Smith RD, Sproston K, Sugden R (2003). What is the value to society of a QALY? Issues raised and recommendations for how to address them. www.publichealth.bham.ac.uk/nccrm/publications.htm 18. Smith RD, Adil M (2004). Measuring the globalisation of health services: a possible index of openness of country health sectors to trade. Globalization, Trade and Health Working Paper, Strategy Unit, Director General’s Office (STU/DGO), World Health Organization, Geneva. 19. Van der Bruggen T, Jansen W, Monnet DL, Smith RD, Verhoef J, Fluit A (2004). Estimating the Public Health Cost of Antimicrobial Resistance in Europe: the example of MRSA. Report to the European Commission (grant QKL2-2002-30599). 20. Holland R, Lenaghan E, Harvey I, Smith RD, Shepstone L, Lipp A, Evans D, Christou M, Blyth A, Maskrey V, Pavey R, Roseveare F (2004). The HOMER trial: Randomised controlled trial of HOme based MEdication Review by pharmacists in Norfolk & Suffolk. Final report to Eastern Region NHS R&D. 21. Smith RD (2005). Infectious disease and risk: lessons from SARS. Report to: The Nuffield Trust, London.
29 22. The SVQ Research Team (2008). Weighting and valuing quality adjusted life years: preliminary results from the social value of a QALY project. Report for the NIHR Methodology Programme, January 2008. 23. Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Odejar M, Pinto Prades J-L, Robinson A, Ryan M, Shackley P, Smith RD, Sugden R, Wildman J. Weighting and valuing quality adjusted life years using stated preference methods: preliminary results from the Social Value of a QALY Project. Health Technology Assessment 2010; Vol. 14: No. 27. 24. Keogh-Brown M, Wren-Lewis S, Edmunds WJ, Beutels P, Smith RD. The possible macroeconomic impact on the UK of an influenza pandemic. Discussion Paper 431 (May 2009), Department of Economics, University of Oxford. 25. Smith RD, Fidler D, Lee K (2009). Global Health Diplomacy Research. Trade, Foreign Policy, Diplomacy and Health Draft Working Paper Series, World Health Organization. 26. Lunt N, Smith RD, Exworthy M, Green ST, Horsfall D, Mannion R (2011). Medical tourism: treatments, markets and health system implications. OECD, May 2011 27. Smith RD, Coast J. The economic burden of antimicrobial resistance. Why it is more serious than current studies suggest. Report to Department of Health (for CMO report), 2013. Available at: www.lshtm.ac.uk/php/economics/assets/dh_amr_report.pdf 28. Taylor J, Hafner M, Yerushalmi E, Smith RD, Bellasio J, Vardavas R, Bienkowska- Gibbs T, Rubin J. Estimating the economic costs of antimicrobial resistance: Model and Results. RAND Europe, prepared for the Independent (O’Neill) Review on Antimicrobial Resistance, Wellcome Trust, 2014. 29. Cummins S, Cornelsen L, Mytton O, Adams J, Iskander D, Knai C, Petticrew M, Scott C, Smith RD, Thompson C, White M. Evaluation of the impact of a levy on added-sugar soft drinks on sales and purchasing behaviour within Jamie's Italian restaurants. Final Report to NIHR Public Health Research Programme, Southampton, 2016. 30. Cornelsen L, Mazzocchi M, Smith RD. Between preferences and references: Evidence from Great Britain on asymmetric price elasticities. Working Paper 139, Department of Statistics, University of Bologna, 2018 (https://ideas.repec.org/p/bot/quadip/wpaper139.html). 31. Egan M, McGill E, Penney T, Anderson de Cuevas R, Er V, Orton L, Lock K, Popay J, Savona N, Cummins S, Rutter H, Whitehead M, De Vocht F, White M, Smith RD, Andreeva M, Meier P, Marks D, Petticrew M. NIHR SPHR Guidance on Systems Approaches to Local Public Health Evaluation. Part 1: Introducing systems thinking. London: National Institute for Health Research School for Public Health Research; 2019 (https://sphr.nihr.ac.uk/wp-content/uploads/2018/08/NIHR-SPHR-SYSTEM- GUIDANCE-PART-1-FINAL_SBnavy.pdf). 32. Egan M, McGill E, Penney T, Anderson de Cuevas R, Er V, Orton L, White M, Lock K, Cummins S, Savona N, Whitehead M, Popay J, Smith RD, Meier P, De Vocht F, Marks D, Andreeva M, Rutter H, Petticrew M. NIHR SPHR Guidance on Systems Approaches to Local Public Health Evaluation. Part 2: What to consider when planning a systems evaluation. London: National Institute for Health Research School for Public Health Research; 2019 (https://sphr.nihr.ac.uk/wp-content/uploads/2018/08/NIHR-SPHR- SYSTEM-GUIDANCE-PART-2-v2-FINALSBnavy.pdf).
OTHER ACADEMIC ACTIVITIES
Journal editorial roles Senior Editor (economics), Social Science & Medicine, 2018-date Associate editor, Health Economics, 2007 to 2018. Associate Editor, Annals of Tropical Medicine & Public Health, 2012 to date Member, editorial board of Journal of Public Health, 2007 to date. Member, editorial board of Globalization and Health, 2007 to 2018. 30 Journals refereed American Economic Review Applied Health Economics and Health Policy Australian and New Zealand Journal of Public Health British Medical Journal British Medical Journal – Global Health Bulletin of the World Health Organization Environmental and Resource Economics European Journal of Health Economics Global Social Policy Globalization and Health Health Affairs Health Economics Health Economics Letters Health Policy Health Economics, Policy and Law Health Policy & Planning International Journal of Public Administration Journal of Development Studies Journal of Economic Psychology Journal of Epidemiology and Community Health Journal of Health Economics Journal of Health Services Research and Policy Journal of Risk Research Medical Decision Making Medical Journal of Australia PharmacoEconomics Public Health Reports Rheumatology Social Science and Medicine The Lancet The Lancet – Global Health Value in Health World Development
Funding proposals refereed Academy of Finland Economic and Social Research Council European Science Foundation Standing Committee of the European Medical Research Councils Genome Canada Medical Research Council studentship/teaching proposals Medical Research Council research and fellowship proposals Department of Health ‘Career Scientist Award’ proposals DH R&D Health Technology Assessment programme research proposals DH NIHR Programme Grants for Applied Research DH NIHR Health Services and Delivery Research DH NIHR Fellowship Career Development Fellowship programme Canadian Social Sciences and Humanities Research Council Food Standards Agency
31 Health, Welfare and Food Bureau (HWFB) of the Hong Kong SAR Government University Grants Committee, Hong Kong The Wellcome Trust research proposals and fellowships Royal Society of New Zealand research proposals National Science Foundation, USA Canada Research Chairs Program National Health and Medical Research Council (Australia) National Research Foundation (NRF), South Africa (Research Chairs) AXA Research Fund
Book proposals refereed Ashgate Publishing Limited book proposals Oxford University Press journal and book proposals Paradigm Publishers Wiley-Blackwell Review
32 ADMINISTRATION AND OTHER DUTIES
University of East Anglia Upon my arrival at UEA I joined Miranda Mugford, as the only other health economist, in developing the Health Economics Group (HEG), which when I left numbered more than 20 staff. Over the time I was there this involved significantly: The development of the HEG strategy and securing ‘core’ funding; Being Deputy Head of Group, undertaking strategic development decisions with Miranda, and deputising at various points on committees etc. Undertaking duties as Head of Group when Miranda is absent, most significantly during her extended period of sickness and study leave absence 01/03/04-30/09/04; Ongoing joint-decision making for strategic, academic and administrative factors affecting the HEG.
UEA moved from a School-based structure to a Faculty-based one, with the Schools of Medicine, Health Policy and Practice, Allied Health Professions and Nursing and Midwifery coming under the Faculty of Health. Formal roles included: 2000-2003, Director of Postgraduate Taught Programmes across the (then) three separate Health Schools. 2004-2007, Research Theme Leader for the Policy & Decision Making Theme within the Faculty of Health. 2004-2007, member of Faculty of Health Research Committee. 2005-2007, member of the Faculty’s “Global Biopolitics Research Group”, directed by Prof. Brian Salter. 2006-2007, member of Advisory Committee for the ‘Global politics of human embryonic stem cell science regulation’ project. Senate representative for MED, 2001 - 2007 Member, UEA Study Leave Committee, 2004 - 2007. Member, UEA Redundancy Committee, 2004 - 2007. Member, Quality Assurance Agency (QAA) Steering Group, 1999/2000. Chair, SPA (Student Progression and Achievement) Aspect Group for QAA, 1999/2000. Member, School Executive, 1999 - 2007. Chair, Health and Safety Committee, 2000. Member, Learning, Teaching and Quality Committee (LTQC), 2000 - 2003. Member, Postgraduate Teaching Committee, 2000 - 2003. Member, Health Economics Support Programme Steering Group, 2000 - 2007. Member, Postgraduate Programme Exam Board, 2000/1 - 2007. MED Representative on Board of Allied Health Professions (AHP), 2002 - 2007.
LSHTM Soon after my arrival at LSHTM I was approached to become Head of Department of what was then the Health Policy Department. I instituted a change of structure, from 7 groups to 3, increased Departmental support for these newly aligned groups and a change in name to Department of Global Health and Development which more accurately reflected the interests and scope of the Department. During my final year I was approached to take over from Anne Mills as Dean of Faculty. Formal roles included: Dean of Faculty of Public Health and Policy, September 2011-2018 Head of Department of Global Health and Development, September 2008-August 2011 GHD Representative on LSHTM Equal Opportunities Committee – September 2009- 2011 and Chair of Equality and Diversity Committee from 2011-2016. GHD Representative on LSHTM Space Management Group – September 2009-2011 PHP Representative on LSHTM Senate – September 2010-August 2013. 33 Exam Board Chair for MSc Global Health Policy, 2011-2015. Chair of LSHTM AMR Centre Steering Committee, 2017-2018.
University of Exeter I joined UoE as the inaugural Deputy Pro Vice Chancellor, to work closely with the PVC in providing strategic leadership and guidance for the College of Medicine and Health (CMH). Specific areas of responsibility relate especially to the management of staff and the daily operations of the College. These include specifically: Leading the development of the College strategy and its implementation, including internal communications, budgeting and annual planning process (PRG) to deliver College strategies and goals. Leading annual HR plan, including workforce planning, Performance Development Reviews, promotion and recruitment, and Equality & Diversity and Athena Swan. Supporting the development and implementation of the College research strategy, especially collaborative partnerships within the wider University, other academic institutions and wider non-academic links in the UK and internationally. Supporting the development and delivery of teaching across the College and enhancing the programme portfolio and our use of digital technology. Formal roles include: CMH Co-Chair, Equality and Diversity Committee, CMH Chair, Athena Swan Committee CMH Member, College Executive Group, CMH Chair, Health, Safety and Wellbeing Committee, CMH Member, International and Development Strategy Group, CMH Member, Education Strategy Group, CMH Chair, Workload Allocation Action Group, CMH
University-wide Member, Global Systems Institute Executive Board, UoE Member, Regional Strategy Group, UoE Member, Cornwall Campuses Strategy Group, UoE Member, joint Cornwall and Campuses Strategy and Executive Group, UoE Member, Senior Management Group, UoE Co-Chair, St Luke’s Strategy Group, UoE Member, Academic Workload Planning Steering Group, UoE Member, Global Systems Institute Executive Group, UoE Member, Institute for Data Science and Artificial Intelligence Executive Board, UoE Member (CMH rep), Positive Working Environment Board, UoE Chair, Senior Posts Steering Group, Wellcome Centre for Communities and Environments in Health, UoE
External committee membership Member, Health Services Research Group, Department of Community Medicine, University of Hong Kong, 1997 – 2000. Member, Health Services Research Forum, Department of Human Services, Melbourne, 1998 - 1999. Member, General Practice Evaluation Program Steering Group, Department of General Practice and Public Health, University of Melbourne, 1998 - 1999. Member, Burden of Illness Steering Group, Eastern Region Health Authority, 2000 - 2001.
34 Member, WHO External Scientific Resource Group (SRG) on Globalization, Trade and Health, STU/DGO, WHO, 2002 - 2007. Member, Scientific Committee, joint Health Economics Study Group and Collège des Economistes de la Santé, Paris, 14th –16th January 2004. Member, Coordinating Committee of the ‘REACT’ NGO, 2004 - 2007. Associate Member, Centre for Medical Genetics and Policy, University of Cambridge, 2004 - 2007. Member, Organising Committee, “Will we respond to antibiotic resistance in time?”. A workshop for the Dag Hammarskjold Foundation, Uppsala, Sweden, 14-17th September, 2005. Member, Organising Committee, “International collaboration on antibiotic resistance: the burden of resistance. A workshop for the European Union, DG Research, Brussels, 7-9 June 2006. Chair, ICEPOP (Investigating Choice Experiments for Preferences of Older People) Advisory Group. MRC Health Services Research Collaboration, University of Bristol, 2005-2009. East of England Regional Funding Committee, National Institute for Health Research: research for Patient Benefit Programme, 2006-2007. Member, iHEA (International Health Economics Association) Scientific Committee, 2006/7. Member, International Scientific Review Committee (ISRC) for Competition III of Genome Canada, 2007. Member, European Health Economics Conference Scientific Committee, 2007/8. Member, European Health Economics Conference Scientific Committee, 2010/11. Member (ESRC representative), Core Scientific Advisory Panel, Environmental and Social Ecology of Human Infectious Diseases (ESEI) initiative, Medical Research Council (MRC), Natural Environment Research Council (NERC), Economic and Social Research Council (ESRC), Biotechnology and Biological Sciences Research Council (BBSRC), 2009-date. Member, Grant Advisory Panel (Panel C, economics), Economic and Social Research Council, 2010-2012 (acting Vice/Chair on number of occasions). Chair, Grant Advisory Panel (Panel C), Economic and Social Research Council, 2012- 2016. Chair, Secondary Data Analysis Initiative (SDAI), Economic and Social Research Council, 2016-2017. Member, International Scientific Review Committee (ISRC) for Large Scale Applied Research Project Competition, Genome Canada, 2010-11 and 2012-13. Member (ESRC representative), Ecology of Infectious Disease (EID) Panel, US National Science Foundation and ESRC joint initiative, 2011 Member (BBSRC representative), Ecology and Evolution of Infectious Disease (EEID) Panel, US National Science Foundation and ESRC joint initiative, 2012 Member, Advisory Committee, “The Complexity of Global Policies: Measurement Methodologies and Application to Global Health Policy”. London School of Economics, 2011. Member, College of Reviewers, Canada Research Chairs Program, 2011-date. Founding Member, Health Diplomacy Network, 2010-date. Member, International Scientific Review Committee for Large-Scale Applied Research Project Competition in Genomics and Personalized Health, Genome Canada, 2012 Member, Strategic Planning core committee, International Health Economics Association, 2013-15. Elected as Honorary Member of Faculty of Public Health, UK, in 2014. Member, ESRC Working Group on social science and antimicrobial resistance, 2014. 35 Member (ESRC representative), cross-council AMR initiative steering group, RCUK, 2014-15. Member, Executive Board, International Health Economics Association, 2015-date (as general elected member to 2019, then as elected HESG representative to date) Member, Executive Committee, International Health Economics Association 2018. Member, Longitude prize award committee, 2014-present Chair, AMR in the Real World scheme, Natural and Environmental Research Council, 2015-2016 Member, Scientific Advisory Board, Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), hosted by the Swedish Research Council, Stockholm, 2017-2021. Member, Scientific Panel, AMR Global Awards, RCUK cross-council initiative, 2017-18. Member, International Scientific Review Committee for Large-Scale Applied Research Project Competition in Genomics and Precision Health, Genome Canada, 2017 Member and vice-chair, Expert Panel on The Potential Socio-economic Impacts of Antimicrobial Resistance in Canada, Canadian Council of Academies, 2018-2019 Chair, International Networking Competition funding panel, Economic and Social Research Council, 2018 Chair, Large Grants Competition, Economic and Social Research Council, 2018-19 Member, UKRI Future Leaders Fellowships Panel (rep from Economic and Social Research Council), 2018-date. Member, International Scientific Advisory Group, ‘Ecologically sympathetic way of managing water in informal settlements’ Wellcome Trust project to the Monash Sustainability Institute, Melbourne, Australia, 2018-date. Chair, Scientific Advisory Group, ‘LifeCourseCap’’, Wellcome Trust Investigator Award for Prof Joanna Coast, University of Bristol, 2019-date. Member, Devon STP (Sustainability and Transformation Partnership) Collaborative Board, 2019-date
Non-executive roles School Governor, St Sidwells Primary School and Nursery, Exeter, 2015-date. o Chair, Resources Committee, 2016-2019 Non-Executive Director, South West Academic Health Science Network, Pynes Hill, Exeter, 2018-date Non-Executive Director, Royal Cornwall Hospitals Trust, Truro, 2019-date o Member, Remuneration Committee o Member, People and Organisational Development committee o Member, Quality Assurance Committee
36 CONTRIBUTION TO NATIONAL, SUBJECT, PROFESSIONAL BODIES
Membership of professional organisations Elected as Honorary Member of Faculty of Public Health, UK, in 2014. International Health Economics Association (Charter Member, member of Strategic Planning core committee 2013-15, elected Board Member 2015-2019, HESG-elected member 2019-2021, and Executive Committee Member 2018-2020). UK Health Economists Study Group. Health Systems Global Society for Genetics Policy and Population Health Health Services Research Network, NHS Confederation. Human Development and Capability Association, Thematic Group on Health and Disability.
Also act as Mentor on formal schemes for HESG, iHEA and University of Exeter, as well as informally.
Expert Advisor Expert in trade for WHO IHR Roster of Experts. Invitation by WHO to lead a ‘WHO Collaborating Centre on Globalisation, Trade and Health’. Expert Advisor role to the WHO on a number of occasions in the fields of: (i) antimicrobial resistance; (ii) globalisation; and (iii) genomics. Expert Advisor role to the WTO on the health aspects of globalisation. Expert Advisor role to the World Bank on the health aspects of globalisation. Expert Advisor role to the OECD on the health aspects of globalisation. Expert Advisor role to the UNCTAD on the health aspects of globalisation. Expert Advisor to the Commission on Macro-economics and Health on the macro- economic impact of antimicrobial resistance. Member, Panel of Experts, WHO Genomic Resource Centre. Expert Consultant and Member, WHO Global Strategy for the Containment of Antimicrobial Resistance. Various country-specific consultation roles, such as the US National Academies of Science, Health Ministries of Viet Nam and The Philippines.
Conference papers 1. Smith RD, Hall J, Gurney HG, Harnett PR. Adjuvant chemotherapy for Dukes’ C colon cancer - a cost-utility analysis. 18th Scientific Meeting of the Clinical Oncological Society of Australia, Sydney, December 1991. 2. Smith RD, Hall J, Gurney HG, Harnett PR. A cost utility analysis of adjuvant chemotherapy for Dukes’ C colon cancer. 24th Annual Conference of the Public Health Association of Australia, Canberra, September 1992. 3. Smith RD, Jan S, Shiell A. The dilemma of expanding health services: capital or labour? A look at radiotherapy. 24th Annual Conference of the Public Health Association of Australia, Canberra, September 1992. 4. Dobson M, Smith RD, Hall J, Gerard K. Do personal factors influence QALY values? 24th Annual Conference of the Public Health Association of Australia, Canberra, September 1992. 5. Smith RD, Jan S, Shiell A. The cost of expanding the provision of radiotherapy services. 43rd Annual General Meeting of the Royal Australasian College of Radiologists, Royal Pines Resort, Gold Coast, October 1992 (invited paper).
37 6. Smith RD. Handling data deficiency in economic evaluation: pick a number? First Annual Public Health Network Conference, Sydney, November 1992. (Awarded Conference Prize). 7. Jan S, Smith RD, Shiell A. Road safety: Does Joan Slater have a point? 15th Annual Conference of the Australian Health Economics Society, Canberra, September 1993. 8. Smith RD, Shiell A, Jan S. Issues associated with valuing the benefits of road safety. 25th Annual Conference of the Public Health Association of Australia, Sydney, October 1993. 9. Scott A, Smith RD. Patience with patient satisfaction. 25th Annual Conference of the Public Health Association of Australia, Sydney, October 1993. 10. Smith RD, Baxter C. A general introduction to the role of Health Economics in multidisciplinary research. Annual Conference of South and West Association of University Departments of General Practice, Bristol, January 1996 (invited paper). 11. Coast J, Smith RD, Millar M. Resistance: the opportunity cost of antibiotic treatment. First World Congress of the International Health Economics Association, Vancouver, May 1996. 12. Smith RD, Coast J. Production externalities in healthcare: the case of antibiotic resistance. 18th Annual Conference of the Australian Health Economics Society, Coffs Harbour Education Campus, Coffs Harbour, July 1996. 13. Smith RD. The use of willingness to pay techniques in outcomes research. Annual Conference of the Association of Regulatory and Clinical Scientists of Australia (ARCS) and the Therapeutic Goods Administration (TGA), Canberra, August 1996 (invited paper). 14. Smith RD, Coast J. The public health threat of antibiotic resistance: an economic policy perspective. 28th Annual Conference of the Public Health Association of Australia, Perth, October 1996. 15. Smith RD, Coast J. Controlling antibiotic resistance: further developments in the transferable permit market. 19th Annual Conference of the Australian Health Economics Society, Melbourne, July 1997. 16. Wilton P, Smith RD. GP budget holding: bullseye or target miss? 19th Annual Conference of the Australian Health Economics Society, Melbourne, July 1997. 17. Olsen JA, Smith RD. Who have been asked to value what? A review of WTP-studies on health and health care. Health Economists Study Group, Galway, July 1998. 18. Smith RD, Olsen JA. From theory to practice: A review of two theoretical arguments for WTP and their application in empirical studies. Second World Congress of the International Health Economics Association, Rotterdam, June 1999 (invited paper). 19. Wilton P, Smith RD. General Practice Reform: an econometric assessment of the impact of patient enrolment and budget-holding. 21st Annual Conference of the Australian Health Economics Society, Canberra, July 1999. 20. Olsen JA, Smith RD, Harris A. Willingness to pay for health: an Economic Exegesis. Health Services Research Conference, Sydney, August 1999. 21. Smith RD, Olsen JA. Construction of the contingent valuation market in health care: a critical assessment. Health Economists Study Group, Newcastle, January 2000. 22. Smith RD, Salter B. Citizen, Consumer Or Both? Re-conceptualising Demand In Health Care. Strategic Issues in Health Care Management, University of St Andrews, April 2000. 23. Coast J, Smith RD, Karcher AM, Wilton P, Millar M. Superbugs II: How should economic evaluation be conducted for interventions which aim to reduce antimicrobial resistance? Health Economists Study Group, Nottingham, July 2000. 24. Smith RD. Issues with long-term effects on the measurement of cost effectiveness. International Conference on Health Research for Development, Bangkok, October 2000 (invited paper).
38 25. Coast J, Smith RD, Millar MR. Disentangling value: assessing the benefits of preventing the emergence and transmission of antimicrobial resistance. International Conference on the Economics of Infectious Disease: LSHTM, London, March 2001. 26. Smith RD, Reed S, Laxminarayan R, Black D, Sullivan S. Economic issues and antibiotic resistance in the community. Third World Congress of the International Health Economics Association, York, July 2001 (invited paper). 27. Coast J, Smith RD, Karcher A, Wilton P, Millar M. Super-bugs II: How should economic evaluation be conducted for interventions which aim to reduce antimicrobial resistance? Health Economics Study Group, Nottingham, July 2001. 28. Coast J, Smith RD, Wilton P, Millar M, Karcher A-M. Economics, interventions and antimicrobial resistance. Third World Congress of the International Health Economics Association, York, July 2001 (invited paper). 29. Jones T, Smith RD, Harris A. Context in a Contingent Valuation: An examination of community valuation of three government services. Third World Congress of the International Health Economics Association, York, July 2001. 30. Holland R, Smith RD, Harvey I, Lenaghan E. Assessing quality of life in the elderly: a comparison of two utility measures. Health Economists Study Group, Brunel, July 2002. 31. Yeung R, Smith RD, Lai-chin W, Chau J, McGhee SM. Diminishing marginal willingness to pay for health benefit: internal and external tests of scope. Health Economists Study Group, Brunel, July 2002. 32. Thorsteinsdóttir H, Smith RD, Daar A. Intellectual Property Rights - Catalyst or Inhibitor of Genomics for Global Health? 3rd International DNA Sampling Conference, Montreal, September 5-8th 2002. 33. Smith RD, Smith JR. The importance of ‘regret’ in determining quality of life and decision making in health care: a psychological and economic perspective. 16th Annual Conference of the European Health Psychology Society, Lisbon, 2-5 October 2002. 34. Holland R, Smith RD, Harvey I, Lenaghan E. Assessing quality of life in the elderly: a comparison of two utility measures. Fifth Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Rotterdam, 3-5 November 2002. 35. Smith RD. The ‘reference price’ effect in WTP studies: reality or illusion? International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada, June 2003. 36. Yago M, Smith RD, Coast J. A Computable General Equilibrium Model of the Economic Impact of Antimicrobial Resistance. International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada, June 2003. 37. Mortimer D, Smith RD, Coast J. Antimicrobial resistance: a micro-economic modeling approach. International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada, June 2003. 38. Holland R, Smith RD, Harvey I, Lenaghan E. Assessing quality of life in the elderly: a comparison of two utility measures. International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada, June 2003. 39. Yeung R, Smith RD, McGhee S. Willingness to pay and sensitivity to scale: the ‘income effect’. International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada, June 2003. 40. Yago M, Smith RD, Coast J. A Computable General Equilibrium Model of the Economic Impact of Antimicrobial Resistance. Fourth World Congress of the International Health Economics Association, San Francisco, June 2003. 41. Mortimer D, Smith RD, Coast J. Antimicrobial resistance: a micro-economic modeling approach. Fourth World Congress of the International Health Economics Association, San Francisco, June 2003.
39 42. Yeung R, Smith RD, McGhee S. Willingness to pay and sensitivity to scale: the ‘income effect’. Fourth World Congress of the International Health Economics Association, San Francisco, June 2003. 43. Yeung R, Lam LK, Smith RD, McGhee S. Bayesian estimates of willingness-to-pay for health benefit. Fourth World Congress of the International Health Economics Association, San Francisco, June 2003. 44. Holland R, Smith RD, Harvey I, Lenaghan E. Assessing quality of life in the elderly: a comparison of two utility measures. Fourth World Congress of the International Health Economics Association, San Francisco, June 2003. 45. Donaldson C, Baker R, Chilton S, Mason H, Jones-Lee M, Loomes G, Metcalf H, Mugford M, Shackley P, Robinson A, Ryan M, Smith RD, Sugden R (alphabetical after first author). The $64,000 (or £30,000) question: willingness to pay for a QALY from a UK perspective. Ninth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington VA, 16-19 May 2004 (invited plenary address). 46. Holland R, Lenaghan E, Harvey I, Smith RD, Shepstone L, Lipp A, Christou M, Evans D. A randomised controlled trial of domiciliary medication review by pharmacists in the elderly. Faculty of Public Health Conference, Edinburgh, June 2004. 47. Donaldson C, Loomes G, Robinson A, Smith RD. A NICE solution to a NICE problem?: A proposed method to assess the societal value of a QALY. Health Economist Study Group, Glasgow, July 2004. 48. Smith RD. Contingent valuation in health care: is there more to it than just health status? Health Economist Study Group, Glasgow, July 2004. 49. Smith JR, Mugford M, Smith RD. Making sense of economic evidence in understanding the value of interventions for severe asthma. Health Economist Study Group, Glasgow, July 2004. 50. Holland R, Lenaghan E, Harvey I, Smith RD, Shepstone L, Lipp A, Christou M, Evans D, Hand C. A randomised controlled trial of domiciliary medication review by pharmacists in the elderly. Society for Social Medicine, Birmingham, September 2004. 51. Smith RD. The reliability of willingness to pay for changes in health status. Fifth European Conference on Health Economics, London School of Economics, 8 – 11 September 2004. 52. Smith RD. Contingent valuation in health care: is there more to it than just health status? Fifth European Conference on Health Economics, London School of Economics, 8 – 11 September 2004. 53. Smith RD. Sensitivity to scale in contingent valuation: the importance of the budget constraint. Fifth European Conference on Health Economics, London School of Economics, 8 – 11 September 2004. 54. Smith RD. Its not what you do, its the way that you do it: a comparison of questionnaire formats and modes of administration for contingent valuation in health care. Fifth European Conference on Health Economics, London School of Economics, 8 – 11 September 2004. 55. Sach T, Smith RD, Whynes D. How deep is the public pocket? A ‘league table’ of willingness-to-pay values. Health Economist Study Group, Oxford, January 2005. 56. Sach T, Smith RD, Whynes D. How deep is the public pocket? A ‘league table’ of willingness-to-pay values across intervention, health problem and country. Fifth World Congress of the International Health Economics Association, Barcelona, June 2005. 57. Frew E, Philips Z, Whynes D, Smith RD, Covey J. How do individuals select WTP values? An explanation from prominence theory. Fifth World Congress of the International Health Economics Association, Barcelona, June 2005. 58. Smith RD. Measuring the ‘openness’ of country health sectors to trade: a suggested methodology. Fifth World Congress of the International Health Economics Association, Barcelona, June 2005.
40 59. Smith RD. Contingent valuation in health care: is there more to it than just health status? Fifth World Congress of the International Health Economics Association, Barcelona, June 2005. 60. Smith RD, Donaldson C, Mason H, Robinson A, Ryan M, Shackley P, Wildman J. A nice solution to a NICE problem? A UK study to assess the societal value of a QALY. Fifth World Congress of the International Health Economics Association, Barcelona, June 2005. 61. Robinson A, Baker R, Smith RD. How do people respond to willingness to pay questions? A review of the qualitative evidence. Health Economist Study Group, Newcastle, July 2005. 62. Robinson A, Baker R, Smith RD. How do people respond to willingness to pay questions? A review of the qualitative evidence. Preference Elicitation Group, Newcastle, September 2005. 63. Holland R, Lenaghan E, Harvey I, Smith RD, Shepstone L, Christou M, Lipp A, Evans D. The HOMER trial: an RCT of medication review in older people. A detailed description of the intervention, and an analysis of whether results differed by pharmacist characteristics. British Pharmaceutical Conference, Manchester, 26-28 September 2005. 64. Robinson A, Baker R, Smith RD. How do people respond to willingness to pay questions? A review of the qualitative evidence. Preference Elicitation Group, Newcastle, September 2005. 65. Nicol A, Smith RD, Smith JR, Mills K, Somerville M, Adams M, Reynolds S. What do patients with rheumatoid arthritis think of shared clinical decision-making? A qualitative observational study of anti-TNF treatment in clinical practice. Annual European Congress of Rheumatology, Amsterdam, 21-24 June 2006 66. Robinson A, Baker R, Bateman I, Donaldson C, Loomes G, Packham C, Pinto JL, Ryan M, Shackley P, Smith RD, Sugden R (alphabetical after first author). Do members of the public wish to give more weight to some QALYs than others?: Results of pilot studies. Seventh European Conference on Health Economics, Budapest, July 2006. 67. Baker R, Donaldson C, Shackley P, Robinson A, Smith RD, Mason H. NICE ways of making health care decisions. Sixth European Conference on Health Economics, Budapest, July 2006. 68. Smith RD. Measuring the globalisation of health services: a possible index of openness of country health sectors to trade. Health Economist Study Group, York, July 2006. 69. Nicol A, Smith RD, Smith JR, Mills KS, Adams M, Reynolds S. Shared decision- making in rheumatoid arthritis: the patients’ view. Third International Conference on Communication in Healthcare, Basle, Switzerland, 5-8 September 2006. 70. Keogh-Brown MR, Smith RD. Evaluating the macro-economic impact of infectious disease. Society for Social Medicine 50th Annual Scientific Meeting, Leeds, 13-15th September 2006. 71. Nicol A, Smith RD, Smith JR, Mills K, Adams M, Reynolds S. Shared clinical decision- making in rheumatology: what do the patients think? Society for Social Medicine 50th Annual Scientific Meeting, Leeds, 13-15th September 2006. 72. Holland R, Brooksby I, Lenaghan E, Ashton K, Hay L, Smith RD, Shepstone L, Howe A, Lipp A, Daly C, Harvey I. A randomised controlled trial of home-based medication review and lifestyle advice by community pharmacists for patients with heart failure. Society for Social Medicine 50th Annual Scientific Meeting, Leeds, 13-15th September 2006. 73. Keogh-Brown M, Smith RD, James S, Sargent T. Smoke or Substance? The Economic Cost of Infectious Disease. Health Economist Study Group, Birmingham, January 2007. 74. Smith RD, Whynes DK, Frew EJ; Philips ZN; Covey J. On precision and prominence in WTP responses. Health Economist Study Group, Birmingham, January 2007.
41 75. Coast J, Smith RD, Lorgelly P. It's not winning that counts, its the taking part: should we be assessing capability rather than achievement? Health Economist Study Group, Birmingham, January 2007. 76. Mills KS, Nicol A, Somerville M, Healey N, Smith RD, Scott DGI. Switching Anti TNF treatment: What do patients think of being offered a choice? British Society of Rheumatology, Birmingham, May 2007. 77. Mills KS, Nicol A, Somerville M, Healey N, Smith RD, Scott DGI. Keen to live until I die: Patients perspectives of the impact of Anti TNF Therapy on their quality of life. British Society of Rheumatology, Birmingham, May 2007. 78. Smith RD. How open to trade is the health sector? Sixth World Congress of the International Health Economics Association, Copenhagen, June 2007. 79. Beutels P, Edmunds JW, Smith RD. Partially wrong? Partial equilibrium and the economic analysis of infectious disease interventions. Sixth World Congress of the International Health Economics Association, Copenhagen, June 2007 (invited paper). 80. Keogh-Brown M, Smith RD, Edmunds JW, Beutels P. Economic Impact Of Influenza: The Macro Perspective. Sixth World Congress of the International Health Economics Association, Copenhagen, June 2007 (invited paper). 81. Sadique MZ, Edmunds WJ, Smith RD, Meerding WJ, de Zwart O, Brug J, Beutels P. Don’t panic! A multi-country population-based survey of precautionary behaviour in response to the perceived threat of pandemic influenza. Sixth World Congress of the International Health Economics Association, Copenhagen, June 2007 (invited paper). 82. Kinghorn P, Smith RD, Robinson A. Developing the Capability Approach to Assess Quality of Life in Patients with Chronic Pain. Sixth World Congress of the International Health Economics Association, Copenhagen, June 2007 (invited paper). 83. Robinson A, Baker R, Donaldson C, Loomes G, Smith RD, Sugden R (alphabetical after lead author). Do Members of the Public Wish to Give More Weight to Some QALYs than Others? Sixth World Congress of the International Health Economics Association, Copenhagen, June 2007. 84. Donaldson C, Smith RD, Ryan M, Abel Olsen J, Brouwer W, Moatti J-P, Persson U, Gyrd-Hansen D, Gulacsi L, Manca A, Kozierkiewicz A, Mataria A, Pinto Prades JL EuroVaQ: the European value of a QALY project. Sixth World Congress of the International Health Economics Association, Copenhagen, June 2007 (invited paper). 85. Coast J, Smith RD, Lorgelly P. Ideas changing health: the influence of Capabilities on health care decision making in the UK. Human Development and Capability Association’s annual conference, New York, September 2007. 86. Smith RD. The process of HTA in the UK. 7th Health Economics International Symposium, Sao Paulo, Brazil August 15 - 17, 2007 (Invited keynote address). 87. Smith RD. HTA: general expectations and lessons learned. 7th Health Economics International Symposium, Sao Paulo, Brazil August 15 - 17, 2007 (Invited keynote address). 88. Kinghorn P, Smith RD. From theory to practice: are we capable of operationalising the Capability Approach? Health Economist Study Group, Norwich, January 2008. 89. Keogh-Brown M, McDonald S, Edmunds J, Beutels P, Smith RD. The macroeconomic costs of a global influenza pandemic. Eleventh Annual Conference on Global Economic Analysis, Helsinki, Finland, June 12-14, 2008. 90. Smith RD, Keogh-Brown M, Barnett A. Modelling the macroeconomic impact of pandemic influenza on the UK economy and finance sector. First Annual Conference on Epidemics, Asilomar, California, December 1-3 2008. 91. Kinghorn P, Robinson A, RD Smith. Can we value ‘capability’? Some findings from a pilot study applying a Multi-Attribute Value Method. Health Economist Study Group, Manchester, January 2009. 92. Keogh-Brown M, Smith RD. The impact of pandemic influenza on the UK economy: crash or bounce? Health Economist Study Group, Manchester, January 2009.
42 93. Smith RD. Trade and health- the role and impact of the private sector. Prince Mahidol Award Conference, Bangkok, 30 January 2009 (invited presentation). 94. Smith RD, Keogh-Brown M, Barnett A. Using Computable General Equilibrium analysis in health economics: an application to pandemic influenza. Seventh World Congress of the International Health Economics Association, Beijing, July 2009 (invited presentation). 95. Smith RD, Keogh-Brown M, MacDonald S, Edmunds J, Beutels P. Estimating the global macroeconomic impact of pandemic influenza and associated mitigation policies. Seventh World Congress of the International Health Economics Association, Beijing, July 2009. 96. Keogh-Brown M, McDonald S, Smith RD, Martinez-Alverez M, Coast J. Global CGE modelling of antibiotic resistance: An application of the GLOBE model. Twelfth Annual Conference on Global Economic Analysis, Santiago, Chile, June 2009. 97. Kinghorn P, Robinson A, Smith RD. Findings from a pilot study applying a Multi- Attribute Value Method: Addressing the suspected presence of part-whole bias. Foundations and Applications of Utility, Risk and Decision Theory (FUR) XIV International Conference, Newcastle University, June 15-18, 2010. 98. Kinghorn P, Robinson A, Smith RD. Valuing capability: Findings from a pilot study applying a Multi-Attribute Value Method. 8th European Conference on Health Economics, Helsinki, 7-10 July 2010. 99. Smith RD, Keogh-Brown MR, Lock K. Mutually exclusive? A healthy diet and a healthy economy. XI International Congress on Obesity, Stockholm, 11-15 July 2010. 100. Martínez Álvarez M, Smith RD, Chanda R. Prospects for Medical Tourism between the UK and India. Symposium on ‘Health Systems, Health Economies and Globalisation’, Kings College, London, 2-3 July 2010. 101. Smith RD. The impact of trade in health services on human resources for health. Prince Mahidol Award Conference, Bangkok, 29 January 2011 (invited presentation). 102. Lagarde M, Pagaiya N, Mullei K, Blaauw D, Smith RD. Are nurses more altruistic than others? Prince Mahidol Award Conference, Bangkok, 29 January 2011. 103. Smith RD, Keogh-Brown M. The macroeconomic impact of pandemic influenza vaccination in a low income setting. Eighth World Congress of the International Health Economics Association, Toronto, July 2011 (invited paper). 104. Martínez Álvarez M, Smith RD, Chanda R. Prospects for Medical Tourism: a case- study of bi-lateral trade between the UK and India. Eighth World Congress of the International Health Economics Association, Toronto, July 2011. 105. Lagarde M, Smith RD, Hanson K, Blouwe D. Does altruism influence job preferences? Evidence from nurses in South Africa. Eighth World Congress of the International Health Economics Association, Toronto, July 2011. 106. Keogh-Brown M, Smith RD. The macro-economic impact of pandemic influenza and associated policies: a developing country perspective. Eighth World Congress of the International Health Economics Association, Toronto, July 2011. 107. Venkatapuram, S, Smith RD. Health, capabilities, and an operational metric. Human Development and Capability Association Conference, The Hague, September 6-8th, 2011. 108. Lagarde M, Blaauw D, Smith RD. Altruism, Identity and Cultural Norms in the Tropics. Economic Science Association European Conference, Luxembourg, September 2011. 109. Yamabhai I, Smith RD. Do patents lead to higher prices? A case study of oncology medicines in Thailand. Royal Society of Tropical Medicine and Hygiene, London, December 14 2011. 110. Stynes G, Smith RD. Could improved training opportunities reduce health workforce migration from sub-Saharan Africa? Evidence from a discrete choice experiment among pharmacists. Health Economist Study Group, Oxford, June 2012.
43 111. Yamabhai I, Smith RD. Patent role in medicine selection of the National List for Essential Medicines: a probit model applied to oncology medicines in Thailand. 11th Annual International Conference on Health Economics, Management and Policy, Athens, 25-28 June 2012. 112. Keogh-Brown M, Tarp-Jensen H, Smith RD. A CGE analysis of the health co- benefits of GHG emission reduction strategies in the UK. EcoMod2012 International Conference on Economic Modeling, Seville, Spain, July 4-6, 2012 113. Lagarde M, Smith RD, Blaauw D. Can we encourage the devotion of nurses? An experimental investigation of the effects of various incentives. European Conference of Health Economics, Zürich, 19-21 July 2012. 114. Yerushalmi E, Hunt P, Hoorens S, Sauboin C, Smith RD. An approach to estimating the impact of malaria prevention with Ghana as a case study: a synthesis between a computable general equilibrium model and health models. Poverty Reduction, Equity and Growth Network (PEGNet) Conference on “How to Make African Economic Lions: Tapping Africa’s Growth and Poverty Reduction Potentials“, Dakar, Senegal, Sept 6-7, 2012. 115. Stynes G, Smith RD, Smith F, Oketch M. Could improved training opportunities reduce health workforce migration from sub-Saharan Africa? Evidence from a discrete choice experiment among pharmacists. Society for Social Medicine 56th Annual Scientific Meeting, London, Sept 12-14, 2012 116. Yerushalmi E, Hunt P, Hoorens S, Sauboin C, Smith RD. Macro-economic impact of reducing malaria: an application of a dynamic general equilibrium modelling to Ghana. ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin. 117. Stynes G, Smith F, Smith RD, Oketch M, Owusu-Daaku F, Lagarde M. Measuring the importance of professional training in the international migration of pharmacists from sub-Saharan Africa. Annual Congress of the International Pharmaceutical Federation. Amsterdam, 3-8 October 2012. 118. Stynes G, Smith RD, Smith F, Oketch M, Owusu-Daaku F, Lagarde M. Has education policy been overlooked in efforts to manage health workforce migration? Results from a discrete choice experiment examining education preferences among pharmacists from sub-Saharan Africa. 2nd Global Symposium on Health Systems Research. Beijing, 31 October – 3 November 2012. 119. Keogh-Brown M, Jensen HT, Smith RD, Chalabi Z, Dangour A, Davies M, Edwards P, Garnett T, Givoni M, Hamilton I, Jarrett J, Roberts I, Wilkinson P, Woodcock J, Haines A. A whole-economy model of the health co-benefits of strategies to reduce greenhouse gas emissions in the UK. PHS conference, London, 23 November 2012. 120. Keogh-Brown M, Jensen HT, Smith RD, Chalabi Z, Dangour A, Edwards P, Garnett T, Givoni M, Griffiths U, Hamilton I, Roberts I, Wilkinson P, Haines A. A whole- economy CGE model of the health co-benefits of UK Greenhouse Gas reduction strategies. Health Economist Study Group, Exeter, January 2013 121. Yerushalmi E, Hunt P, Hoorens S, Sauboin C, Smith RD. The macro-economic impact of reducing malaria: an application of a dynamic general equilibrium modelling to Ghana. Centre for the Study of African Economies Annual conference, Oxford, 17-18 March 2013. 122. Keogh-Brown M, Jensen, HT, Smith RD. Malaria in Ghana: Integrated Macroeconomic and Epidemiological-Demographic Impact Assessment. 16th Annual Conference on Global Economic Analysis, Shanghai, China, June 12-14, 2013. 123. Jensen HT, Keogh-Brown M, Bretscher M, Chico M, Drakeley C, Smith RD. Malaria in Ghana: Integrated Macroeconomic and Epidemiological-Demographic Impact Assessment. 62nd Annual Conference of the American Society of Tropical Medicine and Hygiene, Washington, Nov 13-17, 2013. 124. Cornelsen L, Green R, Turner R, Dangour A, Shankar B, Mazzocchi M, Smith RD. What happens to the pattern of food consumption when food prices change? Evidence
44 from a systematic review and meta-analysis of food price elasticities globally. Third Annual Leverhulme Centre for Integrative Research on Agriculture and Health Conference, London, June 13-14 2013. 125. Smith RD, Keogh-Brown M, Jensen HT, Chalabi Z, Davies M, Dangour A, Edwards P, Garnett T, Givoni M, Griffiths U, Hamilton I, Jarrett J, Roberts I, Wilkinson P, Woodcock J, Haines A. The effect on the UK economy of health co-benefits associated with climate change mitigation strategies. Third Annual Leverhulme Centre for Integrative Research on Agriculture and Health Conference, London, June 13-14 2013. 126. Walls HL, Cornelsen L, Friel S, Smith RD. The impact of international food-related trade policy on nutrition and health: A systematic review. Third Annual Leverhulme Centre for Integrative Research on Agriculture and Health Conference, London, June 13- 14 2013. 127. Smith RD, Keogh-Brown M, Jensen HT, Chalabi Z, Davies M, Dangour A, Edwards P, Garnett T, Givoni M, Griffiths U, Hamilton I, Jarrett J, Roberts I, Wilkinson P, Woodcock J, Haines A. The effect on the UK economy of health co-benefits associated with climate change mitigation strategies. Ninth World Congress of the International Health Economics Association, Sydney, July 2013. 128. Stynes G, Smith RD, Smith F, Lagarde M, Oketch M. Education and international health workforce migration: surveying the mechanics of ‘brain drain’ among pharmacists from sub-Saharan Africa. Ninth World Congress of the International Health Economics Association, Sydney, 7-10 July 2013. 129. Stynes G, Lagarde M, Smith RD, Smith F, Oketch M, Owusu-Daaku F. Health workers’ stated preferences for overseas versus local professional education: a discrete choice experiment. Ninth World Congress of the International Health Economics Association, Sydney, 7-10 July 2013. 130. Stynes G, Smith RD, Smith F, Lagarde M, Oketch M. Professional education preferences and international migration: implications for health workforce policy from a discrete choice experiment among pharmacists. Economics of the Health Workforce, Sydney, 7-10 July 2013. 131. Hanefeld J, Horsfall D, Lunt N, Smith RD. Medical tourism—cure or malaise for the National Health Service: a mixed methods study. Public Health Science: A National Conference Dedicated to New Research in UK Public Health, London, Nov 29 2013. 132. Cornelson L, Green R, Dangour A, Shanker B, Smith RD. Systematic review and meta-regression of food price elasticities? do methods of demand analysis matter? Health Economics Study Group, Sheffield, 8-10 Jan 2014. 133. Keogh-Brown M, Smith RD, Jensen HT, Bretscher M, Chico M, Drakely C. An integrated macroeconomic, epidemiological and demographic model framework for policy analysis Health Economics Study Group, Sheffield, 8-10 Jan 2014. 134. Kabujuluzi J, Keogh-Brown M, Smith RD. Macroeconomic implications of health sector reforms: A computable general equilibrium analysis of creating fiscal space for health in Uganda. Centre for the Study of African Economies Annual Conference, Oxford, 23-25 March 2014. 135. Walls H, Smith RD, Drahos P. Improving the regulatory capacity of developing countries to manage risks associated with trade agreements. LCIRAH conference, 2-3 June 2014. 136. Walls HL, Cornelsen L, Smith RD. Political priority accorded nutrition in agricultural trade policy: A case study of the EU's Common Agricultural Policy. LCIRAH conference, 2-3 June 2014. 137. Smith RD. Biting off more than we can chew? Globalization and implications for agriculture and health. LCIRAH conference, 2-3 June 2014. 138. Cornelson L, Green R, Dangour A, Shanker B, Smith RD. Changing food prices and its effect on food consumption in low-income countries. iHEA/ECHE Congress, Dublin, 14-17 July 2014.
45 139. Smith RD. E-learning & MOOCs: LSHTM experience. Keynote address to East- West Alliance Global Symposia, Li Ka Shing Faculty of Medicine, Hong Kong University, 27 October 2014. 140. Walls HL, Tak M, Dixon J, Hanefeld J, Hull E, Smith RD, Johnston D. The impact of agricultural input subsidies on nutrition and health outcomes: A review and mapping of case studies. LIDC Biennial Conference: Interdisciplinary research for development. London, 2015. 141. Smith RD. Estimating the economic impact of the build-up of AMR. Tenth World Congress of the International Health Economics Association, Milan, 11-15 July 2015. 142. Cornelsen L, Mazzocchi M, Smith RD. Impact of food taxes vs subsidies: are price elasticities symmetric to price increases and decreases? Tenth World Congress of the International Health Economics Association, Milan, 11-15 July 2015. 143. Keogh-Brown M, Tarp Jensen H, Smith RD. Macroeconomic Impact of Alzheimer’s Disease in China. Tenth World Congress of the International Health Economics Association, Milan, 11-15 July 2015. 144. Cuevas S, Smith RD, Tarp Jensen H, Keogh-Brown M. Integrating macroeconomic and health analysis: the role of computable general equilibrium models in health economics. Tenth World Congress of the International Health Economics Association, Milan, 11-15 July 2015. 145. Cornelsen L, Mazzocchi M, Smith RD. Implications of asymmetry in consumers’ responses to price changes – the case of health related food taxes and subsidies. Health Economics Study Group, Manchester, 6-8 January 2016. 146. Tarp Jensen H, Keogh-Brown M, Smith RD, Basu S, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Thaiprasert N, Shankar B. Application of a fully integrated Macroeconomic-Environmental-Demographic-health (MED-health) model framework: The case of palm oil in Thailand. 19th Annual Conference on Global Economic Analysis, Washington, June 15-17, 2016. 147. Tuomisto HL, Scheelbeek P, Chalabi Z, Ezzati M, Green R, Haines A, Myers S, Smith RD, Dangour AD. Interactions between environmental change, agriculture, nutrition and health: an evidence-based framework. AgMIP6 Global Workshop, 28-30 June 2016, Montepellier, France. 148. Cornelsen L, Adams J, Gasparrini A, Iskander D, Knai C, Mytton O, Petticrew M, Scott C, Smith RD, Thompson C, White M, Cummins S. Impact of a levy on sales of sugar-sweetened beverages within Jamie's Italian restaurants: interrupted time-series analysis. Public Health Science: A National Conference Dedicated to New Research in UK Public Health, London, Nov 24, 2016. 149. Hanefeld J, Chetty C, Charalombus S, Parker C, Shezi S, Walker R, de Gruchy T, Makandwa T, Vearey J, Modesinyane M, Gilson L, Lunt N, Walls H, Smith RD. Understanding the impact of patient mobility and migration on health systems: a case- study in Southern Africa. Fourth Global Symposium on Health Systems Research, Vancouver, 17 November 2016. 150. Marten R, Hanefeld J, Smith RD. Understanding how states exert power in global health: the post-2015 Sustainable Development Goals. Fourth Global Symposium on Health Systems Research, Vancouver,18 November 2016. 151. Walls HL, Hanefeld J, Modisenyane M, Vearey J, Lunt N, Smith RD. Governance of trade in health services: An analysis of bilateral agreements between South Africa and neighbouring countries. Fourth Global Symposium on Health Systems Research, Vancouver, 17 November 2016. 152. Quirmbach D, Cornelsen L, Smith RD, Jebb S, Marteau T. What is the impact on alcohol purchases of increasing the price of sugary drinks?? Health Economists Study Group, Birmingham, 4-6 January 2017. 153. Quirmbach D, Cornelsen L, Smith RD. Changing the price of sugar-sweetened beverages: what is the effect on the demand for drinks and snacks more widely in the
46 UK? Conference on “The role of taxation and other economic incentives in promoting healthier lifestyles: a focus on tobacco, alcohol and unhealthy diets”. Law and NCD Unit, University of Liverpool London Campus, 17 January 2017. 154. Quirmbach D, Cornelsen L, Smith RD. Impact on non-alcoholic beverage sales of a 10 pence levy on sugar-sweetened beverages within a national chain of restaurants in the UK: interrupted time-series analysis. Conference on “The role of taxation and other economic incentives in promoting healthier lifestyles: a focus on tobacco, alcohol and unhealthy diets”. Law and NCD Unit, University of Liverpool London Campus, 17 January 2017. 155. Quirmbach D, Cornelsen L, Smith RD. The impact of sugar-sweetened beverage price changes on the demand for drinks and snacks in the UK. International Health Policy Conference, London School of Economics & Political Science, February 16-19 2017. 156. Kabujuluzi J, Keogh-Brown M, Smith RD. The welfare implications of healthcare financing reforms: A Macro-Micro simulation analysis of Uganda. Centre for the Study of African Economies Annual Conference, Oxford, 19-21 March 2017. 157. Jensen HT, Keogh-Brown, Smith RD, et al. Palm oil policy in Thailand: An Integrated Assessment of Health, Environmental and Economic Implications (POSHE project). Inaugural Planetary Health Alliance (PHA) conference, Boston MA, April 2017. 158. Adams J, Briggs A, Cummins S, Harrington R, Monsivais P, Mytton O, Penney T, Rayner M, Rutter H, Scarborough P, Smith RD, White M (alphabetical). Theorising how the UK Soft Drinks Industry Levy could impact population level diet and health: development of a multi-sectoral systems map. International Society of Behavioural Nutrition and Physical Activity Annual Meeting, University of Victoria, Canada, 7-10 June 2017. 159. Tarp Jensen H, Keogh-Brown M, Smith RD, Basu S, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Thaiprasert N, Shankar B. Palm oil production and health spillover effects among South, South East and East Asian nations: A fully integrated regional Macroeconomic-Environmental-Demographic-health model. 20th Annual Conference on Global Economic Analysis, Purdue University, West Lafayette IN, June 2017. 160. Tarp Jensen H, Keogh-Brown M, Shankar B, Basu S, Cuevas S, Dangour A, Gheewala SH, Green R, Joy E, Thaiprasert N, Smith RD. An integrated macroeconomic, demographic and health modelling framework for palm oil policies in Thailand. International Conference on Economic Modeling – EcoMod2017 – Ljubljana, Slovenia, 5-7 July 2017. 161. Laura Cornelsen, Matthew Quaife, Mylene Lagarde, Smith RD. Revealed vs stated choice: impact of a tax on sugar-sweetened beverages on the demand for non-alcoholic drinks among households with children in the UK. HESG Aberdeen July 2017 162. Quirmbach D, Cornelsen L, Marteau T, Jebb S, Smith RD. What is the impact on alcohol purchases of increasing the price of sugary drinks? Twelfth World Congress of the International Health Economics Association, Boston, 8-11 July 2017. 163. Watt T, Cornelsen L, Smith RD. Promotions, prices and purchases. Health Economists Study Group meeting, City University, 10-12th January 2018. 164. Kabajulizi J, Keogh-Brown MK, Smith RD. The macroeconomic implications of public healthcare financing: a computable general equilibrium analysis of Uganda. 21st Annual Conference on Global Economic Analysis, Cartagena, Colombia, June 2018 (submitted). 165. Smith RD. Shaping the future of health policy: the role of trade. European Health Economics Association (EuHEA) Conference, Maastricht, 11-14 July 2018 (invited keynote address). 166. Cornelsen L, Quaife M, Lagarde M, Smith RD. Impact of a tax on sugar-sweetened beverages on the choice of non-alcoholic drinks among households with children in the
47 UK from stated preferences. European Health Economics Association (EuHEA) Conference, Maastricht, 11-14 July 2018. 167. Berger N, Cummins S, Smith RD. The role of out-of-home food and beverage consumption in tackling poor diet: a case study of Britain. European Health Economics Association (EuHEA) Conference, Maastricht, 11-14 July 2018. 168. Oppong R, Smith RD, Little P, Verheij T, Butler C, Goossens H, Coenen S, Jowett S, Roberts T, Achana F, Stuart B, Coast J. Cost-effectiveness of internet-based training on antibiotic prescribing for acute respiratory-tract infections in Europe. European Health Economics Association (EuHEA) Conference, Maastricht, 11-14 July 2018. 169. Smith RD, Cornelson L, Jebb S, Marteau T, Quirmbach D. Reducing sugar consumption: are sweet snacks more sensitive to price increases than sugar-sweetened beverages? European Health Economics Association (EuHEA) Conference, Maastricht, 11-14 July 2018. 170. Mazalale J, Johnston D, Matita M, Chirwa EW, Quaife M, Smith RD, Walls H. Designing a discrete choice experiment to understand food choices based on maize price variations in rural Malawi. ANH Academy Conf, Accra, Ghana, 25-29 June 2018. 171. Walls HL, Mazalale J, Katsande A, Johnston D, Chirwa E, Matita M, Smith RD. Impact of agricultural input subsidy programmes in Malawi on end-points in the causal pathway to nutrition and related health: A systematic review. ANH Academy Conf, Accra, Ghana, 25-29 June 2018. 172. Walls HL, Johnston D, Tak M, Dixon J, Hanefeld J, Hull E, Smith RD. The impact of agricultural input subsidies on food and nutrition security: A review and mapping of case-studies. ANH Academy Conf, Accra, Ghana, 25-29 June 2018. 173. Berger N, Cummins S, Smith RD, Cornelsen L. Nutritional content of household food purchases: study of trends and socio-economic inequalities in Britain 2012-2017. Society for Social Medicine 62nd Annual Scientific Meeting, Glasgow, 5-7 September 2018. 174. Penney T, Adams J, White M, Briggs A, Cummins S, Mytton O, Rayner M, Rutter H, Scarborough P, Harrington R, Smith RD. Industry reactions to the UK Soft Drinks Industry Levy: Unpacking the evolving discourse from announcement to implementation. Society for Social Medicine 62nd Annual Scientific Meeting, Glasgow, 5-7 September 2018. 175. Egan M, McGill E, Penney T, Petticrew M, Smith RD. Evaluation of public health interventions using a complex systems lens: a critical review. Public Health Science: A National Conference Dedicated to New Research in UK Public Health, Belfast, 23 November, 2018. 176. Law C, Cornelsen L, Adams J, Penney T, Rutter H, White M, Smith RD. Market reaction to the UK Soft Drinks Industry Levy announcements: Event study analysis of soft drink companies quoted on the London Stock Exchange. 13th World Congress of the International Health Economics Association, Basel, 13-17 July 2019. 177. Roope L, Smith RD, Pouwels K, Buchanan J, Abel L, Eibich P, Butler C, San Tan P, Walker S, Robotham J, Wordsworth S. The challenge of Antimicrobial Resistance: What economics can contribute. 13th World Congress of the International Health Economics Association, Basel, 13-17 July 2019. 178. Watt T, Cornelsen L, Beckert W, Smith RD. The impact of price promotions on demand and consumption of food and drink. 13th World Congress of the International Health Economics Association, Basel, 13-17 July 2019. 179. Berger N, Cummins S, Smith RD, Cornelsen L. Changes in the sugar content of food purchases and socio-economic inequalities: a longitudinal study of British households 2014-2017. Society for Social Medicine & Population Health and International Epidemiology Association European Congress Joint Annual Scientific Meeting, University College Cork, Ireland, September 4-6, 2019.
48 Conference organisation/other 1. Organised session (with Jo Coast) on ‘The economics of antimicrobial resistance’ for the Third International Health Economics Association Conference, York, July 2001. 2. Local organiser, Health Economists Study Group meeting, University of East Anglia, 7- 9th January 2002. 3. Discussant and chair on numerous occasions each year, and member of scientific committee for joint HESG/CES meeting in Jan 2004. 4. Invited Chair of ‘Economy and Public Health’ theme for conference on ‘the future of Health: burdens, challenges and opportunities’, Judge Business School, University of Cambridge, 12-13 July 2006. 5. Co-organiser, Health Economists Study Group meeting, University of East Anglia, 9-11th January 2008. 6. Organised session (with Arnab Acharya) on ‘The macroeconomics of health and development’ for the Seventh World Congress of the International Health Economics Association, Beijing, July 2009. 7. Session co-ordinator for “Trade in health services and impact on HRH”, 2nd Global Forum on Human Resource for Health, Bangkok, Thailand, 25-29 January 2011. 8. Organised “Health Economics: coming of Age” conference at LSHTM, 11 June 2014. 9. Organised session (with Laura Cornelsen) on ‘Modelling the Impact of Food-Price Based Policies on Food Purchasing Behaviour using Household Level Scanner Data’ for the Tenth World Congress of the International Health Economics Association, Milan, 11-15 July 2015. 10. Organised session (with Laura Cornelsen) on ‘Food Prices, Food Availability and Nutrition’ for the 10th World Congress of the International Health Economics Association, Milan, 11-15 July 2015. 11. Organised session (with Laura Cornelsen) on ‘Do, and how do, soda taxes work?’ for the 12th World Congress of the International Health Economics Association, Boston, 8-11 July 2017. 12. Organised session (with Emma Frew) on ‘Beyond causes and consequences: how can economics help tackle childhood obesity?’ 12th World Congress of the International Health Economics Association, Boston, 8-11 July 2017. 13. Economics of Obesity Special Interest Group pre-conference workshop (with Emma Frew), 13th World Congress of the International Health Economics Association, Basel, 13-17 July 2019. 14. Organised session on ‘Evaluating Taxes on Sugar-Sweetened Beverages: How Are We Doing It?’ (with Laura Cornelsen) 13th World Congress of the International Health Economics Association, Basel, 13-17 July 2019. 15. Organised session on ‘Antimicrobial Resistance: What Solutions Can Economists Bring to This Challenge? (with Laurence Roope)’ 13th World Congress of the International Health Economics Association, Basel, 13-17 July 2019.
Other invited presentations 1. Measuring utility values for QALYs: two methodological issues. Health Economics Research Unit, University of Aberdeen, July 1992. 2. Economic issues in antibiotic resistance. CHPE, Monash University, June 1997. 3. Conduct and application of willingness to pay in health care. CHPE, Monash University, June 1998. 4. Antibiotic Resistance: Global Policies and Options. Center for International Development, Harvard University, February 28th 2000. 5. Citizen, Consumer Or Both? Re-conceptualising Demand In Health Care. UEA Schools of Health Open Seminar Series, March 2000. 6. Cost-effectiveness of interventions to tackle antimicrobial resistance: a review of the literature. World Health Organisation, Geneva, 26th June 2000.
49 7. Development of a model to assess the cost-effectiveness of interventions to tackle antimicrobial resistance. World Health Organisation, Geneva, 26th June 2000. 8. The ‘public good’ characteristics of antimicrobial resistance. The Commission on Macroeconomics and Health, World Health Organisation, Geneva, 11th September 2000. 9. Economics of antimicrobial resistance. The Nuffield Trust, London, 11th December 2000. 10. Global public goods for health. World Health Organisation, Geneva, 11th January 2001. 11. Economics of antibiotic resistance. Resources for the Future, Washington DC, 5th April 2001. 12. Global Health and Global Security – a policy imperative? The Nuffield Trust, London, 10th April 2001. 13. Global public goods for health: concepts and policy issues. Global Public Goods for Health Experts Workshop, International Development Research Centre/Canadian International Development Agency/Health Canada, Ottawa, 4th-6th June 2001 14. Antimicrobial resistance and Global Public Goods for Health. Global Public Goods for Health Experts Workshop, International Development Research Centre/Canadian International Development Agency/Health Canada, Ottawa, 4th-6th June 2001 15. Economics and superbugs: is resistance futile? Department of Community Medicine, University of Hong Kong, Hong Kong, 17th October 2001. 16. Determinants of antibiotic use in primary health care. European Conference on Antibiotic Use in Europe (Belgian Antibiotic Policy Coordination Committee & European Union Commission), Brussels, 15-17th November 2001. 17. Health, Global Public Goods and Poverty Reduction: investing in Global Public Goods to Improve Health and Reduce Poverty. Canadian International Development Agency, Ottawa, 11th December 2001. 18. Global Public Goods and Health. Health Canada, Ottawa, 12th December 2001. 19. Global Public Goods for Health: Rhetoric or substance? University of Toronto Joint Centre for Bioethics, Toronto, 13th December 2001. 20. Antimicrobial resistance: what economics has to offer. Forum on Emerging Infections, US Institute of Medicine, The National Academy of Sciences, Washington, 6-7th February 2002. 21. Superbugs: what does economics have to offer in the war against antimicrobial resistance? Breaking our of the box – the benefits of multi-disciplinary research. Norwich Research Park, Norwich, 5th March 2002. 22. Intellectual Property Rights - Catalyst or Inhibitor of Genomics for Global Health? University of Toronto Joint Centre for Bioethics, Toronto, 26th August 2002. 23. Global Public Goods for Health: Rhetoric or substance? Department of Community Medicine, University of Hong Kong, Hong Kong. 21st October, 2002. 24. The General Agreement on Trade in Services and health. WHO External Scientific Resource Group (SRG) on Globalisation, Trade and Health, The Nuffield Trust, 19th –20th March 2003. 25. Measuring trade in health services. Workshop on Trade in Health Services and GATS. University of Ottawa, Canada, 9th –11th July 2003. 26. A general framework for analysing trade in health services. Workshop on Trade in Health Services and GATS. University of Ottawa, Canada, 9th –11th July 2003. 27. A framework for analysing foreign direct investment and commercial presence in health services trade. Workshop on Trade in Health Services and GATS. University of Ottawa, Canada, 9th –11th July 2003. 28. Global Public Goods for Health: Rhetoric or substance? Health Economics Unit, Faculty of Business and Economics, Monash University, Australia, 10th September 2003. 29. The economic impact of SARS. Department of Community Medicine, University of Hong Kong, Hong Kong, 17th September, 2003.
50 30. Innovation: new antibiotics and other technologies. The Dag Hammarskjold Foundation, Uppsala, Sweden, 16th September, 2005. 31. Infectious disease and risk: lessons from SARS. The Nuffield Trust, 20th July, 2005. 32. Contingent valuation in health care: is there more to it than just valuing health status? Health Economics Research Group, Brunel University, 6th June 2005. 33. Infectious disease and risk: lessons from SARS. The Nuffield Trust, 6th May, 2005. 34. What is the value to society of a QALY? Health Economics Research Centre, University of Oxford, 1st March 2005. 35. The estimated economic impact of SARS. Faculty of Medicine, University of Toronto, 27th January, 2004. 36. A review of methods for estimating the economic impact of communicable disease outbreaks. Faculty of Medicine, University of Toronto, 27th January, 2004. 37. Epidemiology and macro-economic modelling. The Nuffield Trust, 2nd March 2004. 38. Health economics and genetics. Public Health Genetics Unit, University of Cambridge, 25th March 2004. 39. Health economics ‘futures’. The Nuffield Trust, 28th April 2004. 40. Antibiotic resistance: the faceless threat. The Dag Hammarskjold Foundation, Uppsala, Sweden, 7th May 2004. 41. Priority setting and innovation. The Nuffield Trust, 9/10th June, 2004. 42. Approaches to measuring trade in health services. WHO Regional (EMRO) Workshop on Research Methodology in Trade in Health Services. Hammamat, Tunisia, 11th June 2004. 43. Issues in measuring foreign direct investment. University of Lausanne, Switzerland, 18th June, 2004. 44. Trade in health services and GATS – a framework for country analysis. University of Lausanne, Switzerland, 19th June, 2004. 45. Trade in health services and GATS – a framework for country analysis. World Health Organisation Western Pacific Region seminar on trade liberalisation and public health, Melia Hotel, Hanoi, Vietnam, 25th August, 2004. 46. Development of CV in health over the past 20 years. University of Newcastle Business School, 29th September 2004. 47. Assessing the macroeconomic impact of infectious disease: the application of Computable General Equilibrium analysis to antimicrobial resistance. Health Protection Agency, London, 2nd November 2004. 48. What is the value to society of a QALY? Health Economics Research Centre, University of Oxford, 1st March 2005. 49. Infectious disease and risk: lessons from SARS. The Nuffield Trust, 6th May, 2005. 50. Contingent valuation in health care: is there more to it than just valuing health status? Health Economics Research Group, Brunel University, 6th June 2005. 51. Infectious disease and risk: lessons from SARS. The Nuffield Trust, 20th July, 2005. 52. Innovation: new antibiotics and other technologies. The Dag Hammarskjold Foundation, Uppsala, Sweden, 16th September, 2005. 53. Rule of rescue: the economist’s perspective. National Institute for Health and Clinical Excellence, 26th January 2006. 54. Global health governance: how much will it cost and where will the funds come from? German Overseas Institute, Hamburg, Germany, 24th February 2006. 55. The (economic) burden of resistance: methods and issues. Workshop on International collaboration on antibiotic resistance. European Commission, DG Research, Brussels 7-9 June 2006. 56. The HeartMed trial: an RCT of home-based medication review and lifestyle advice by community pharmacists in heart failure. Department of Health, 16 June 2006. 57. Trade in Health Services and GATS. Workshop on Health Policy in a Globalizing World, WHO, Geneva, 20-23 June 2006.
51 58. Calculating the effect on the UK economy of an influenza epidemic. Paper for “Policy and Social Science Aspects of Pandemic Influenza Workshop”, IIASA Vienna, 4-5 August, 2006. 59. Global public good aspects of communicable disease control. Paper for “Policy and Social Science Aspects of Pandemic Influenza Workshop”, IIASA Vienna, 4-5 August, 2006. 60. Fighting MRSA: Making Drugs from Bugs. BA Festival of Science, Norwich, 2-9 September 2006. 61. POM to P: will the four horsemen of the apocalypse please saddle up! Norfolk Pharmacists Association meeting, 30 November 2006. 62. Macro-economics and health. South East Asia Office of the WHO, Delhi, 6 March 2007. 63. Globalization and health: panacea or poison? Faculty of Health, University of East Anglia, 21 March 2007. 64. Should we help respondents to ‘construct’ their willingness to pay? Health Economics Research Unit, University of Aberdeen, 29 March 2007. 65. Global Public Goods for Health. Training course on ‘Health Policy in a Globalizing World’, Institut Universitaire de Hautes Etudes Internationales (HEI), Geneva, 20 June 2007. 66. Economic power and global health governance: who’s in control? Griffith University, Brisbane, September 4 2007 67. What is the social value of a QALY? Results (so far!) of a UK population survey. Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, 5 September 2007. 68. Globalization and the macro-economics of health. Centre for Health Economics, Monash University, Melbourne, 6 September 2007. 69. Globalization and the macro-economics of health. Centre for Applied Economic and Social Research, University of Melbourne, Melbourne, 7 September 2007. 70. Macroeconomics and trade environment. Centre for Trade Policy and Law, Carleton University, Ottawa, 11 October 2007. 71. Trade in harmful and hazardous products. Centre for Trade Policy and Law, Carleton University, Ottawa, 11 October 2007. 72. Global Change and Health: Mapping the Challenges of Global Non-Healthcare Influences on Health. Department of Foreign Affairs and International Trade, Ottawa, 26 March 2008. 73. Global Change and Health: Mapping the Challenges of Global Non-Healthcare Influences on Health. Global Health Diplomacy and Chronic Disease Prevention Workshop, Carleton University, Ottawa, 27 March 2008. 74. Globalization: panacea or poison for public health? Section of Public Health and Health Policy, University of Glasgow, 15 May 2008. 75. Computable general equilibrium analysis in health care. WHO Consultation on methods for identifying the economic consequences of diseases and injuries, Venice, 12-13 June 2008. 76. Global Change and health: mapping the challenges of global non-healthcare influences on health. Training course on ‘Health Policy in a Globalizing World’, Institut Universitaire de Hautes Etudes Internationales (HEI), Geneva, 20 June 2008. 77. Measuring the economic impact of AMR: a ‘macro’ approach. Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections (ARHAI), London, 24 September 2008. 78. Modelling the economic impact of pandemic influenza. MRC Infections & Immunity Board Workshop “Building a case for investing in research in environmental & social ecology of human infectious disease”, London, 3 November 2008.
52 79. Global Change and health: mapping the challenges of global non-healthcare influences on health. Training course on ‘Global Health Diplomacy’ for the Chinese Ministry of Health, World Health Organization, Geneva, 21 November 2008. 80. The Crisis in Global Finance and Trade: What are the Implications for Health? Symposium for UCL Institute for Global Health, University College London, 21 January 2009. 81. Health as a Global Public Good. Workshop on Transboundary Crisis Management as a European Public Good, Swedish Institute of International Affairs, Stockholm, 28 January 2009 (presented by Kelley Lee). 82. The macro economic consequences of outbreaks. Symposium on “Vaccination 2009: global public health security - protection against emerging infections”, hosted by Advisory Board of the Netherlands Vaccine Institute, Utrecht, 6 February 2009 (presented by Marcus Keogh-Brown). 83. Trade in Foodstuffs: Impact on Diet and Food Safety. Vietnam Ministry of Health, Hanoi, 26 February 2009. 84. Global change and health. Meeting on ‘Global Health Diplomacy Network’, Rockefeller Foundation, Bellagio, Italy, 26 March 2009. 85. Trade in Health Services. “International Trade in Services Course”, World Bank, Washington DC, 30 March 2009 (with Nick Drager). 86. Mapping of funding for research on health and international relations, focusing on Global Diplomacy. Meeting on ‘Global Health Diplomacy Network’, Rockefeller Foundation, Bellagio, Italy, 3 June 2009. 87. Should other countries import NICE? Health Economics and Health Systems Seminar, LSHTM, 17 June 2009. 88. Prospects for Medical Tourism between India and the UK. Asia-Pacific Technology Network seminar on “Medical Tourism/Elective Surgery in Asia”, London, 13th April 2010 (presented by Melisa Martinez-Alvarez). 89. How might healthcare better assess the impact of resistance? An economic model for determining the societal costs. British Society for Antimicrobial Chemotherapy, London, 24th May 2010 (presented by Marcus Keogh-Brown). 90. Modelling the ‘whole economy’ impact of disease: insights and issues. Health Economics Research Centre, Department of Public Health, University of Oxford, 15 June 2010. 91. Modelling the ‘whole economy’ impact of disease: insights and issues. School of Health and Related Research, University of Sheffield, 17 June, 2010. 92. Modelling the ‘whole economy’ impact of disease: insights and issues. Centre for Health Economics, University of York, 1 July 2010. 93. Modelling the ‘whole economy’ impact of disease: insights and issues. School of Management Science, McGill University, 15 July, 2010. 94. Health, agricultural and economic effects of adopting healthy diet recommendations. 2nd International Roadmap Development Workshop, McGill World Platform for Health and Economic Convergence, Montreal, 29 September, 2010. 95. Developing a whole-economy modelling approach to P. falciparum control in Ghana and Mozambique. Malaria centre Retreat, Oxford, 24-25 March 2011 (presented by Marcus Keogh-Brown). 96. How to swallow the unpalatable: the essential dilemma for economics and ethics. Clinical Ethics Open Day, Imperial College Healthcare NHS Trust Clinical Ethics Committee, 11 May 2011. 97. When health systems fail…to look beyond their borders! Research Network for Health Systems and Infectious Disease, launch conference, London, 17 May 2011. 98. Trade and health. Plenary Panel for “Global health and trade: a forum for academic, business and civil society engagements with UK and EU policy on trade in health, agriculture and food”. European Commission Representation Office, London, 22 June 2011.
53 99. Trade and health. Plenary address for “Global Health Conference: Trading Health”. Department of Health, London, 16 November 2011. 100. A whole-economy analysis of the economic effects of GHG emission reduction strategies and health co-benefits. Health Economics Seminar series, LSHTM, 25/01/12 (presented by Marcus Keogh-Brown). 101. Globalization, trade and health. Global Health Lecture Series, LSHTM, 20/02/12. 102. Macroeconomic modelling of health: the CGE method (with Keogh-Brown, M). Department of Health, London, 02/05/12 103. Macro-economics of disease prevention policies. Science Symposium on Sustaining Disease Prevention, Clare College, Cambridge, 26/10/12. 104. Investing in global infectious disease research. The Royal Society of Medicine, London, 13/11/12. 105. Infectious disease and ‘the economy’. Medical Research Club, UCL, 14/11/12. 106. The Political Economy of Virus Control. STEPS Centre and the Centre for Global Health Policy, Institute of Development Studies, University of Sussex, 11/01/13 107. Medical tourism: a prescription for the NHS? Health Economics and Systems Analysis Group, LSHTM, 12/02/13 108. Medical Schools are not good for health. The Royal Society of Medicine, London, 14/05/13. 109. Medical Tourism and the NHS: cost or benefit? Health Economics Unit, University of Birmingham, 16/04/13 110. Global Health Diplomacy: an introduction. Meeting on ‘Global Health Diplomacy, Universal Coverage and Health Technology Assessment’, Rockefeller Foundation, Bellagio, Italy, 6 August 2013. 111. “It’s the economy, stupid!” The importance of looking ‘beyond health (care)’. University of Warwick Medical School, Warwick, 13 March 2014. 112. Economic Considerations in Responding to the Challenge of Antimicrobial Resistance. The ethics of antimicrobial resistance symposium, Brocher Foundation, Geneva, 27-28 March 2014 (presented by Joanna Coast). 113. The Health Economics of Global Trade. Centre for Health Economics, University of York, 1 May 2014 114. Ebola and Emerging Infectious Diseases: Measuring the Risk. Royal Institute of International Affairs, Chatham House, London, 6 May 2014 115. The Bugs Bite Back: Avoiding the antibiotic apocalypse. Pint of Science Festival, 18- 20 May 2015: www.pintofscience.com 116. The Economics of Resistance. Institut Pasteur, Infection and Epidemiology Department seminar, Paris, 1 June 2015. 117. Fat taxes & thin subsidies: is demand response symmetric. Workshop on Public policy, innovation and productivity, University of Bologna, 12 June 2015 (presented by Mario Mazzocchi) 118. The economic impact of infectious disease outbreaks. Royal Institute of International Affairs, Chatham House, London, 12 October 2015 119. Reflections on the Centre for Health Economics. Centre for Health Economics 25th Anniversary, Monash University, 17 November 2015. 120. “It’s the economy, stupid!” The importance of the ‘macro’ economics of health. Centre for Health Economics, Monash University, 18 November 2015. 121. “It’s the economy, stupid!” The importance of the ‘macro’ economics of health. The Nossal Institute, University of Melbourne, 19 November 2015. 122. The impact of international food-related trade policy on nutrition and health: A systematic review. Trondheim Trade and Health Meeting. Trondheim, Norway, 2016 (presented by Walls HL.
54 123. Seeing the wood as well as the trees: the importance of the ‘macro’ perspective for public health. Bradford Hill Lecture, Cambridge Institute of Public Health, University of Cambridge, 11 March 2016. 124. Implications of asymmetry in consumer response to price change – the case of health- related food taxes and subsidies. LSHTM Health Economics seminar, 18 May 2016 (presented by Laura Cornelsen). 125. Modelling the ‘whole economy’ impact of disease. Pirbright Institute Scientific Seminar Series, Woking, 19 May 2016. 126. “It’s the economy, stupid!”: 'whole economy’ modelling of health (care). Centre for Health Economics & Medicines Evaluation, Bangor University, 31 May 2016. 127. Reorienting Health Systems. Workshop on ‘Health Systems for Ageing Societies in Asia and the Pacific’, Nossal Institute for Global Health, University of Melbourne, 26 October 2016. 128. Macroeconomic Perspective for Prevention of NCDs. Workshop on ‘Health Systems for Ageing Societies in Asia and the Pacific’, Nossal Institute for Global Health, University of Melbourne, 27 October 2016. 129. Making health systems more flexible and more sustainable for ageing populations. Health Systems for the ‘Third Age’, Nossal Institute for Global Health, University of Melbourne, 28 October 2016. 130. A behavioural economic model of alcohol advertising and price. Health Economics Journal Club, School of Population and Public Health, University of British Columbia, Vancouver, 16 November 2016. 131. Understanding the impact of patient mobility and migration on health systems: a case-study in Southern Africa. Faculty of Health Sciences Research Seminar Series, Simon Fraser University, Vancouver, 17 November 2016. 132. Talk about complex! Why a seemingly simple population intervention requires a system level evaluation: the case of the UK Soft Drinks Industry Levy. "We need to talk about complexity" Nuffield Department of Primary Care Health, University of Oxford, Oxford, 13/14 June 2017 (presented by Martin White). 133. Can we tax our way to better health? Dalla Lana School of Public Health, University of Toronto, Canada, 13 November 2017. 134. Impact of a tax on sugar-sweetened beverages on the choice of non-alcoholic drinks among households with children in the UK from stated preferences (presented by Laura Cornelsen). Department of Economics, University of Reading, 24 November 2017. 135. Impact of a tax on sugar-sweetened beverages on the choice of non-alcoholic drinks among households with children in the UK from stated preferences. Faculty of Health and Medicine, Lancaster University, 29 November 2017. 136. The University, the College…and me! ENSURE Programme, Chinese University of Hong Kong, Hong Kong, 25 February 2019. 137. “If you don’t manage your time, someone else will”. Yes, but how?. iHEA ECR network webinar, 15 March 2019. 138. Reducing sugar consumption: a taxing problem. Centre for the Business and Economics of Health, Faculty of Business, Economics & Law, University of Queensland, 29 July 2019. 139. “It’s the economy, stupid!”: 'whole economy’ modelling of health (care). Centre for the Business and Economics of Health, Faculty of Business, Economics & Law, University of Queensland, 31 July 2019.
55